<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cardiovasc Drugs Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Cardiovasc Drugs Ther</journal-id>
<journal-title-group>
<journal-title>Cardiovascular Drugs and Therapy</journal-title>
</journal-title-group>
<issn pub-type="ppub">0920-3206</issn>
<issn pub-type="epub">1573-7241</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28721524</article-id>
<article-id pub-id-type="pmc">5550530</article-id>
<article-id pub-id-type="publisher-id">6735</article-id>
<article-id pub-id-type="doi">10.1007/s10557-017-6735-0</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Human iPSC-Derived Cardiomyocytes for Investigation of Disease Mechanisms and Therapeutic Strategies in Inherited Arrhythmia Syndromes: Strengths and Limitations</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Casini</surname>
<given-names>Simona</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Verkerk</surname>
<given-names>Arie O.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0095-0084</contrib-id>
<name>
<surname>Remme</surname>
<given-names>Carol Ann</given-names>
</name>
<address>
<phone>+31-20-5663263</phone>
<email>C.A.Remme@amc.uva.nl</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000084992262</institution-id><institution-id institution-id-type="GRID">grid.7177.6</institution-id><institution>Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, </institution><institution>University of Amsterdam, </institution></institution-wrap>Room K2-104-2, Meibergdreef 15, PO Box 22700, 1100 DE Amsterdam, The Netherlands </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000084992262</institution-id><institution-id institution-id-type="GRID">grid.7177.6</institution-id><institution>Department of Medical Biology, Academic Medical Center, </institution><institution>University of Amsterdam, </institution></institution-wrap>Amsterdam, The Netherlands </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>18</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>18</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<volume>31</volume>
<issue>3</issue>
<fpage>325</fpage>
<lpage>344</lpage>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">During the last two decades, significant progress has been made in the identification of genetic defects underlying inherited arrhythmia syndromes, which has provided some clinical benefit through elucidation of gene-specific arrhythmia triggers and treatment. However, for most arrhythmia syndromes, clinical management is hindered by insufficient knowledge of the functional consequences of the mutation in question, the pro-arrhythmic mechanisms involved, and hence the most optimal treatment strategy. Moreover, disease expressivity and sensitivity to therapeutic interventions often varies between mutations and/or patients, underlining the need for more individualized strategies. The development of the induced pluripotent stem cell (iPSC) technology now provides the opportunity for generating iPSC-derived cardiomyocytes (CMs) from human material (hiPSC-CMs), enabling patient- and/or mutation-specific investigations. These hiPSC-CMs may furthermore be employed for identification and assessment of novel therapeutic strategies for arrhythmia syndromes. However, due to their relative immaturity, hiPSC-CMs also display a number of essential differences as compared to adult human CMs, and hence there are certain limitations in their use. We here review the electrophysiological characteristics of hiPSC-CMs, their use for investigating inherited arrhythmia syndromes, and their applicability for identification and assessment of (novel) anti-arrhythmic treatment strategies.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Induced pluripotent stem cells</kwd>
<kwd>Cardiomyocytes</kwd>
<kwd>Human</kwd>
<kwd>Arrhythmias</kwd>
<kwd>Pharmacology</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001826</institution-id>
<institution>ZonMw</institution>
</institution-wrap>
</funding-source>
<award-id>113303006</award-id>
<award-id>91714371</award-id>
<principal-award-recipient>
<name>
<surname>Remme</surname>
<given-names>Carol Ann</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media, LLC 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par2">Life-threatening ventricular arrhythmias and sudden arrhythmic death typically occur in the setting of common cardiovascular pathologies associated with structural cardiac abnormalities, including myocardial ischemia/infarction, heart failure, and cardiomyopathy. In a subset of patients, often relatively young and otherwise healthy individuals, ventricular arrhythmias are the consequence of an inherited arrhythmia syndrome. Here, mutations in genes encoding ion channels, transporters, interacting proteins, or regulatory pathways lead to potentially pro-arrhythmic alterations of cardiac electrophysiological properties [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Since correction of the genetic defect is as yet impossible, pharmacological treatment strategies are generally aimed at preventing or counteracting the detrimental functional effects of the mutation. In some cases, implantation of an implantable cardioverter defibrillator (ICD) is the only option for preventing sudden arrhythmic death, but ICD implantation may be associated with serious side effects and lower quality of life [<xref ref-type="bibr" rid="CR3">3</xref>]. During the last two decades, significant progress has been made in the identification of genetic defects underlying inherited arrhythmia syndromes, which has provided some benefit through elucidation of gene-specific arrhythmia triggers and treatment, most notably for Long QT syndrome [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, for most arrhythmia syndromes, clinical management is hindered by insufficient knowledge of the functional consequences of the mutation in question, the pro-arrhythmic mechanisms involved, and hence the most optimal treatment strategy. Moreover, disease expressivity and sensitivity to therapeutic interventions often varies between mutations and/or patients, underlining the need for more individualized strategies.</p>
<p id="Par3">Following identification of a putative mutation in a patient with an inherited arrhythmia syndrome, its functional consequences may be investigated in vitro. In the case of mutations in ion channel genes or known regulatory proteins, the impact on (dys)function of the ion channel in question is typically investigated through current measurements (using patch clamp analysis) in heterologous expression systems in which the mutated ion channel of interest is expressed (i.e., <italic>Xenopus</italic> oocytes, human embryonic kidney or HEK cells, and Chinese Hamster Ovary or CHO cells) [<xref ref-type="bibr" rid="CR5">5</xref>]. This approach allows for elucidation of the effect of the mutation on current density, kinetics, and sensitivity to certain drugs. While certainly informative, these expression systems do not necessarily reflect the situation in the endogenous cardiomyocyte (CM) since they often lack accessory proteins and other cellular components required for proper ion channel function. Transgenic mice carrying specific mutations overcome many of these limitations. However, while recent progress (i.e., CRISPR-Cas9 technology) has significantly decreased both time and costs related to the generation of such mouse models, they are not suitable for high-throughput screening of rare inherited arrhythmia mutations. Mice display crucial differences in cardiac electrophysiological characteristics as compared to humans, including a high heart rate and a relatively short action potential secondary to differences in potassium currents [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Moreover, transgenic mouse models lack the disease variability commonly observed in patients secondary to genetic background, comorbidity, and environmental factors. Hence, the electrophysiological consequences of mutations associated with inherited cardiac arrhythmias are ideally investigated in human CMs. However, the latter are not widely available since obtaining cardiac biopsies from patients is a highly invasive procedure and not without risk. Furthermore, it is difficult to keep human adult CMs in culture, limiting their applicability for more long-term studies.</p>
<p id="Par4">The development of the induced pluripotent stem cell (iPSC) technology now provides the opportunity for generating and culturing iPSC-derived cardiomyocytes obtained from human material (human-induced pluripotent stem cell (hiPSC)-CMs) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. These hiPSC-CMs enable investigation of patient- and/or mutation-specific disease mechanisms as well as identification and assessment of novel therapeutic strategies for arrhythmia syndromes. However, due to their relative immaturity, hiPSC-CMs also display a number of essential differences as compared to adult human CMs, and hence there are certain limitations in their use. The purpose of this review is to evaluate the applicability of hiPSC-CMs for investigation of inherited arrhythmia syndromes and assessment of (novel) anti-arrhythmic treatment strategies. To this end, we describe the electrophysiological characteristics of hiPSC-CMs, the various available tools for their functional analysis, and their strengths and limitations. In addition, we present an overview of pharmacological studies employing hiPSC-CMs models of inherited arrhythmia syndromes.</p>
</sec>
<sec id="Sec2">
<title>General Characteristics of hiPSC-CMs</title>
<p id="Par5">Generation of hiPSCs starts by obtaining somatic cells from easily accessible human material, such as hair, blood, skin, fat, urine, or oral mucosa. These cells are reprogrammed to a pluripotent state by introducing pluripotency-associated genes, and hiPSCs thus generated can be kept in culture indefinitely. Next, hiPSCs are differentiated towards the cardiac lineage through a number of strategies (for review, see [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]). After approximately 8–12 days, areas of beating cells typically appear, which can be microscopically dissected and dissociated into single CMs for subsequent electrophysiological and immunofluorescence analysis. This approach, which is both laborious and expensive, enables generation of patient-specific hiPSC-CMs for electrophysiological and pharmacological investigations. Today, hiPSC-CMs are also commercially available; these control lines can be used to introduce mutations using CRISPR-Cas9 technology followed by functional studies [<xref ref-type="bibr" rid="CR12">12</xref>]. Conversely, isogenic lines can be created by repairing the mutation, thus serving as patient-specific controls [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. While they facilitate investigations in a human cardiomyocyte environment, an important limitation of hiPSC-CMs relates to the fact that they are immature and in fact share more similarities with fetal than with adult human CMs (for review, see [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]). Typically, hiPSC-CMs express high levels of cardiac-specific genes (including Nkx2.5, cardiac troponin T, α-myosin heavy chain, α-actinin, myosin light chain 2, etc.) and display a striated pattern for α-actinin and myosin light chain, comparable to adult ventricular myocardium [<xref ref-type="bibr" rid="CR17">17</xref>]. However, adult CMs are rod shaped and elongated, while hiPSC-CMs usually have a more round or multi-angular shape and are smaller in size (Fig. <xref ref-type="fig" rid="Fig1">1</xref>a). Moreover, in contrast to adult CMs, hiPSC-CMs display relatively disorganized sarcomeres and typically lack t-tubuli [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. The relative intrinsic immaturity of hiPSC-CMs is also reflected in important differences in functional characteristics as compared to adult CMs, including electrophysiology and excitation–contraction coupling. A number of approaches have been developed to enhance hiPSC-CMs maturity (see “<xref ref-type="sec" rid="Sec21">Approaches for Improved Electrophysiological Measurements in hiPSC-CMs</xref>” section) leading to improved contractile, calcium handling, and electrophysiological properties [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Nevertheless, the intrinsic properties of hiPSC-CMs need to be considered when employing these cells for investigation of arrhythmia disease mechanisms and assessment of (novel) therapeutic strategies.<fig id="Fig1"><label>Fig. 1</label><caption><p>Morphological and electrophysiological phenotype of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and native human ventricular cardiomyocytes (CMs). <bold>a</bold> Morphological differences between human adult ventricular CMs and hiPSC-CMs; note the different scale. <bold>b</bold> Examples of action potential (<italic>solid line</italic>) and calcium transient (<italic>dashed line</italic>) in human adult ventricular CMs and hiPSC-CMs (<italic>upper panels</italic>), and schematic representation of the time course and magnitude of relevant ion currents (<italic>lower panels</italic>). Figure modified from [<xref ref-type="bibr" rid="CR68">68</xref>] (<bold>a</bold>) and [<xref ref-type="bibr" rid="CR15">15</xref>] (<bold>b</bold>)</p></caption><graphic id="MO1" xlink:href="10557_2017_6735_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec3">
<title>Electrophysiological Characteristics of hiPSC-CMs</title>
<sec id="Sec4">
<title>Action Potential</title>
<p id="Par6">The cardiac action potential (AP) is divided in five different phases, i.e., phase 0 to 4 (Fig. <xref ref-type="fig" rid="Fig1">1</xref>b). The AP is initiated by a large, rapid influx of sodium (Na<sup>+</sup>) through Na<sup>+</sup> channels, resulting in fast depolarization of the cell membrane, the so-called upstroke or phase 0 of the AP. Following the AP upstroke, there is a brief repolarizing phase (phase 1), resulting from efflux of potassium (K<sup>+</sup>) caused by activation of the transient outward K<sup>+</sup> current (<italic>I</italic>
<sub>to1</sub>). Next, inward flow of calcium (Ca<sup>2+</sup>) through L-type Ca<sup>2+</sup> current (<italic>I</italic>
<sub>CaL</sub>) leads to the plateau phase (phase 2). Finally, the membrane repolarizes to its original state due to activation of the rapid and slow delayed rectifier K<sup>+</sup> channels (conducting the <italic>I</italic>
<sub>Kr</sub> and <italic>I</italic>
<sub>Ks</sub> currents, respectively) in phase 3 of the AP. Adult ventricular and atrial cardiomyocytes (but not nodal cells) also exhibit phase 4 in which the resting membrane potential (RMP) remains constant due to the presence of the inward rectifying K<sup>+</sup> current <italic>I</italic>
<sub>K1</sub>. With the use of the patch clamp technique, various AP parameters can be analyzed which reflect specific membrane current functions. These parameters include RMP or maximal diastolic potential (MDP), cycle length, AP amplitude, AP upstroke velocity, and AP duration (APD) at various levels of repolarization (i.e., APD<sub>20</sub>, APD<sub>50</sub>, and APD<sub>90</sub>) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a). For example, the RMP or MDP is an indication for steady-state K<sup>+</sup> currents, such as <italic>I</italic>
<sub>K1</sub>. AP upstroke velocity is a measure of sodium current (<italic>I</italic>
<sub>Na</sub>) availability, while the various AP durations (APDs) reflect the various phases of repolarization consequent to the differential contribution of various membrane currents. APD<sub>20</sub> is for example importantly regulated by <italic>I</italic>
<sub>CaL</sub> and <italic>I</italic>
<sub>to1</sub>, while APD<sub>90</sub> is importantly set by <italic>I</italic>
<sub>Ks</sub> and <italic>I</italic>
<sub>Kr</sub> (although some overlap exists).<fig id="Fig2"><label>Fig. 2</label><caption><p>Examples of techniques used for electrophysiological measurements in hiPSC-CMs. <bold>a</bold> hiPSC-CMs patched with manual anpatch clamp technique (<italic>upper panel</italic>). Typical AP trace recorded in hiPSC-CMs with the use of the patch clamp technique (<italic>lower panel</italic>). <bold>b</bold> Cluster of hiPSC-CMs seeded on multi-electrode arrays (<italic>MEAs</italic>) (<italic>upper panel</italic>). Field potential trace obtained with MEAs (<italic>lower panel</italic>). Assessable parameters are indicated in the corresponding figures. <italic>APD</italic>
<sub><italic>20</italic></sub>, <italic>APD</italic>
<sub><italic>50</italic></sub>, and <italic>APD</italic>
<sub><italic>90</italic></sub> action potential duration at 20, 50, and 90% repolarization; <italic>APA</italic>
<sub><italic>max</italic></sub> maximal AP amplitude; <italic>RMP</italic> resting membrane potential; <italic>MDP</italic> maximal diastolic potential; <italic>dV/dt</italic>
<sub><italic>max</italic></sub> maximal upstroke velocity; <italic>FPD</italic> field potential duration. Upper panel reproduced from [<xref ref-type="bibr" rid="CR122">122</xref>]</p></caption><graphic id="MO2" xlink:href="10557_2017_6735_Fig2_HTML"></graphic></fig>
</p>
<p id="Par7">The most common hiPSCs differentiation protocols predominantly generate cells classified as ventricular-like hiPSC-CMs [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], although protocols aimed at specifically generating atrial-like [<xref ref-type="bibr" rid="CR24">24</xref>] and nodal-like hiPSC-CMs [<xref ref-type="bibr" rid="CR25">25</xref>] have also been recently described. The distinction between hiPSC-CMs cell type is often made based on AP phenotype, with a more negative MDP, a rapid AP upstroke, and a long plateau phase for ventricular-like APs. It is however questionable whether the subdivision in the various cell types based only on the AP shape is correct, since APs in hiPSC-CMs resemble a fetal-like phenotype. Single-cell mRNA expression measurements of hiPSC-CMs following patch clamp analysis have demonstrated a good correlation between expression of specific myocyte-lineage markers and designation of AP as ventricular-like, atrial-like, and nodal-like based on cellular electrophysiological features [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. However, caution should be taken when applying this selection method, since the cutoff values for the AP duration and upstroke velocities for the various cell types are arbitrary and differ among studies. The presence of specific currents may also be used to distinguish atrial and nodal CMs in the hiPSC-CMs population, such as the ultra-rapid delayed rectifier K<sup>+</sup> current (<italic>I</italic>
<sub>Kur</sub>) and the acetylcholine-sensitive K<sup>+</sup> current (<italic>I</italic>
<sub>KACh</sub>) for atrial cells [<xref ref-type="bibr" rid="CR24">24</xref>] and the “funny current” (<italic>I</italic>
<sub>f</sub>) and T-type Ca<sup>2+</sup> current (<italic>I</italic>
<sub>CaT</sub>) for nodal cells (see also “<xref ref-type="sec" rid="Sec5">Ion currents</xref>” section) [<xref ref-type="bibr" rid="CR25">25</xref>].</p>
<p id="Par8">Comparison of hiPSC-CMs AP characteristics among various studies is difficult due to differences in experimental conditions used (variable recording temperatures, perforated vs. whole-cell configuration technique, spontaneous beating cells vs. triggered cells). Nevertheless, the most remarkable difference between hiPSC-CMs and native CMs relates to the observation that in most studies, hiPSC-CMs (including ventricular-like and atrial-like cells) by themselves are spontaneously active, with beating rates of approximately 30 to 120 beats per minutes (for review, see [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]). Moreover, APs recorded in ventricular-like hiPSC-CMs present intrinsically less negative RMP/MDP, lower upstroke velocity, and a less prominent notch (phase 1) as compared to freshly isolated human ventricular adult CMs [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>] (Fig. <xref ref-type="fig" rid="Fig1">1</xref>b). These characteristics reflect the relative immature state of hiPSC-CMs and constitute potential limitations for their use as adequate models of arrhythmia syndromes. However, certain technical approaches and experimental protocols may be employed to overcome these limitations (see “<xref ref-type="sec" rid="Sec21">Approaches for Improved Electrophysiological Measurements in hiPSC-CMs</xref>” section).</p>
</sec>
<sec id="Sec5">
<title>Ion Currents</title>
<p id="Par9">Because of the clear differences in AP shape between native, adult CMs, and hiPSC-CMs, it is likely that differences exist in the functional availability of the various cardiac ion channels due to differences in density and gating properties. Thus, before establishing hiPSC-CMs as a cellular model for investigating cardiac arrhythmia syndromes, it is important to carry out a detailed comparison between ion currents in hiPSC-CMs with those in native CMs (Fig. <xref ref-type="fig" rid="Fig1">1</xref>b). Such a comparison remains difficult, since only few studies have investigated in detail ion current characteristics in healthy, adult human ventricular CMs. Furthermore, ionic current properties are dependent on experimental conditions and protocols, as well as tissue heterogeneity (transmural, atrial vs. ventricle vs. nodal). Moreover, it should be noted that ion channel function is tightly regulated by accessory subunits, interacting proteins, and intracellular metabolism. Knowledge of these regulatory factors and processes in hiPSC-CMs is still rudimentary, but they are likely not identical to those in the adult (human) ventricular CMs. In the sections below, an overview is presented of the characteristics of the major ion currents in hiPSC-CMs (for details, see Table <xref ref-type="table" rid="Tab1">1</xref>). Table <xref ref-type="table" rid="Tab2">2</xref> lists the most relevant inhibitors typically used to study the various currents. Since mostly ventricular-type hiPSC-CMs are obtained with the currently used differentiation protocols, a comparison is made between hiPSC-CMs and healthy native human ventricular CMs, unless stated otherwise.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Biophysical properties of ion currents in hiPSC-CMs and healthy human ventricular myocytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th>Cell type</th><th>Current density (pA/pF)</th><th>Refs</th><th>
<italic>V</italic>
<sub>1/2</sub> of activation (mV)</th><th>Refs</th><th>
<italic>V</italic>
<sub>1/2</sub> of inactivation (mV)</th><th>Refs</th><th>Recovery from inactivation (ms)</th><th>Refs</th></tr></thead><tbody><tr><td rowspan="2">
<italic>I</italic>
<sub>Na</sub>
</td><td>hiPSC-CMs</td><td>From −12.2<sup>a</sup> to −272.2</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]</td><td>From −25.5 to −42.4</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]</td><td>From −61.4 to −85.0</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]</td><td>
<italic>τ</italic> = 60.4<break></break>
<italic>t</italic>
<sub>1/2</sub> = 10.8<break></break>
<italic>τ</italic>
<sub>f</sub> = 6.4, 6.0<break></break>
<italic>τ</italic>
<sub>s</sub> = 103.6, 118.1</td><td>[35, 37, 40, 108]</td></tr><tr><td>Human VM</td><td>−49.0</td><td>[<xref ref-type="bibr" rid="CR38">38</xref>]</td><td>−51.0</td><td>[<xref ref-type="bibr" rid="CR38">38</xref>]</td><td>−102.0</td><td>[<xref ref-type="bibr" rid="CR38">38</xref>]</td><td>NA</td><td>NA</td></tr><tr><td rowspan="2">
<italic>I</italic>
<sub>CaL</sub>
</td><td>hiPSC-CMs</td><td>From −6.6 to ~−58</td><td>[<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]</td><td>From ~−12 to ~−28</td><td>[<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]</td><td>−29.1, ~−45</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]</td><td>NA</td><td>NA</td></tr><tr><td>Human VM</td><td>−10.2, −3.8</td><td>[<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]</td><td>−4.7, −4.2</td><td>[<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]</td><td>−19.3, −23.5</td><td>[<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]</td><td>NA</td><td>NA</td></tr><tr><td rowspan="4">
<italic>I</italic>
<sub>to1</sub>
</td><td>hiPSC-CMs</td><td>From ~1.3 to ~19</td><td>[<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]</td><td>From ~10 to ~20</td><td>[<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]</td><td>~−40, −41.1</td><td>[<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]</td><td>
<italic>τ</italic>
<sub>f</sub> = 200<break></break>
<italic>τ</italic>
<sub>s</sub> = 2380</td><td>[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td>Human sub-epi VM</td><td>6.8, 10.6</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]</td><td>9.7, 29.1</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]</td><td>−31.9, −9.5</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]</td><td>
<italic>τ</italic> = 24<break></break>
<italic>τ</italic>
<sub>s</sub> = 9621<break></break>
<italic>τ</italic>
<sub>f</sub> = 46.1</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td>Human sub-endo VM</td><td>4.4, 2.6</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]</td><td>23.1, 32.0</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]</td><td>−25.3, −17.6</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]</td><td>
<italic>τ</italic>
<sub>f</sub> = 25.0, 90.6<break></break>
<italic>τ</italic>
<sub>s</sub> = 328.0, 3109.0</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td>Human VM</td><td>9.3, 8.5<sup>b</sup>
</td><td>[<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]</td><td>~30, ~20</td><td>[<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]</td><td>−27.3</td><td>[<xref ref-type="bibr" rid="CR51">51</xref>]</td><td>
<italic>τ</italic> = 27.8</td><td>[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td rowspan="2">
<italic>I</italic>
<sub>Kr</sub>
</td><td>hiPSC-CMs</td><td>From ~0.18 to ~2.5</td><td>[<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR53">53</xref>–<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>From ~−10 to ~−36</td><td>[<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]</td><td>NA</td><td></td><td>NA</td><td></td></tr><tr><td>Human VM</td><td>0.31, ~0.25, ~0.6</td><td>[<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]</td><td>~+22, −5.74</td><td>[<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]</td><td>NA</td><td></td><td>NA</td><td></td></tr><tr><td rowspan="2">
<italic>I</italic>
<sub>Ks</sub>
</td><td>hiPSC-CMs</td><td>From 0.22 to ~2.9</td><td>[<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]</td><td>From ~−10 to ~+22</td><td>[<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]</td><td>X</td><td></td><td>X</td><td></td></tr><tr><td>Human VM</td><td>0.18</td><td>[<xref ref-type="bibr" rid="CR60">60</xref>]</td><td>NA</td><td></td><td>X</td><td></td><td>X</td><td></td></tr><tr><td rowspan="2">
<italic>I</italic>
<sub>K1</sub>
</td><td>hiPSC-CMs</td><td>From ~−0.8 to −5.1</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]</td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td></tr><tr><td>Human VM</td><td>From −3.6 to −32.1</td><td>[<xref ref-type="bibr" rid="CR68">68</xref>]</td><td>X</td><td></td><td>X</td><td></td><td>X</td><td></td></tr><tr><td rowspan="2">
<italic>I</italic>
<sub>f</sub>
</td><td>hiPSC-CMs</td><td>−4.1, −0.9, ~−3.0</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]</td><td>−84.6</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>]</td><td>X</td><td></td><td>X</td><td></td></tr><tr><td>Human VM</td><td>−1.18</td><td>[<xref ref-type="bibr" rid="CR71">71</xref>]</td><td>−110, −80.0</td><td>[<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]</td><td>X</td><td></td><td>X</td><td></td></tr></tbody></table><table-wrap-foot><p>
<italic>I</italic>
<sub><italic>Kr</italic></sub> and <italic>I</italic>
<sub><italic>Ks</italic></sub> density measurements refer to maximal peak tail current, except for the studies of Sala et al. [<xref ref-type="bibr" rid="CR14">14</xref>], Terrenoire et al. [<xref ref-type="bibr" rid="CR40">40</xref>], and Ma et al. [<xref ref-type="bibr" rid="CR30">30</xref>] where <italic>I</italic>
<sub>Kr</sub> and <italic>I</italic>
<sub>Ks</sub> are measured at the end of the depolarizing step; </p><p>
<italic>VM</italic> ventricular myocytes; <italic>V</italic>
<sub><italic>1/2</italic></sub> (in)activation, half-voltage of (in)activation; <italic>τ</italic>
<sub><italic>f</italic></sub> and <italic>τ</italic>
<sub><italic>s</italic></sub> fast and slow time constants of recovery from inactivation, respectively; <italic>τ</italic> time constant of recovery from inactivation (curve fitted with a mono-exponential equation); <italic>t</italic>
<sub><italic>1/2</italic></sub> time for half of the channels to recover from inactivation; in hiPSC-CMs, <italic>I</italic>
<sub>to1</sub> density is measured at +40 mV, while in human VM is measured between +40 and +60 mV; <italic>I</italic>
<sub><italic>k1</italic></sub> density values are measured at −100 mV; <italic>X</italic> channel property does not exist; <italic>NA</italic> not assessed or measured; ~estimated from figure; <italic>sub-epi</italic> subepicardial myocytes; <italic>sub-endo</italic> subendocardial myocytes</p><p>
<sup>a</sup>
<italic>I</italic>
<sub>Na</sub> recorded with low extracellular sodium (7 mM Na<sup>+</sup>) solution [<xref ref-type="bibr" rid="CR108">108</xref>]</p><p>
<sup>b</sup>Average <italic>I</italic>
<sub>to1</sub> density between 0 and +60 mV [<xref ref-type="bibr" rid="CR51">51</xref>]</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Blockers commonly used to investigate specific ion currents</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ion current</th><th>Blockers</th></tr></thead><tbody><tr><td>Sodium current (<italic>I</italic>
<sub>Na</sub>)</td><td>Flecainide, TTX</td></tr><tr><td>L-type calcium current (<italic>I</italic>
<sub>CaL</sub>)</td><td>Nifedipine</td></tr><tr><td>T-type calcium current (<italic>I</italic>
<sub>CaT</sub>)</td><td>Nickel</td></tr><tr><td>Late sodium current (<italic>I</italic>
<sub>NaL</sub>)</td><td>GS967, ranolazine</td></tr><tr><td>Transient outward potassium current (<italic>I</italic>
<sub>to1</sub>)</td><td>4-Aminopyridine</td></tr><tr><td>Rapid delayed rectifier potassium current (<italic>I</italic>
<sub>Kr</sub>)</td><td>E-4031</td></tr><tr><td>Slow delayed rectifier potassium current (<italic>I</italic>
<sub>Ks</sub>)</td><td>JNJ303, chromanol 293B</td></tr><tr><td>Inward rectifier potassium current (<italic>I</italic>
<sub>K1</sub>)</td><td>Barium</td></tr><tr><td>“Funny” current (<italic>I</italic>
<sub>f</sub>)</td><td>Ivabradine</td></tr></tbody></table><table-wrap-foot><p>
<italic>TTX</italic> tetrodotoxin</p></table-wrap-foot></table-wrap>
</p>
<sec id="Sec6">
<title>Sodium Current (<italic>I</italic><sub>Na</sub>)</title>
<p id="Par10">The cardiac sodium channel Na<sub>v</sub>1.5, encoded by the <italic>SCN5A</italic> gene, carries the inward <italic>I</italic>
<sub>Na</sub> which is responsible for the rapid upstroke of the AP in CMs and consequently for proper cardiac excitability and impulse propagation. In the majority of studies, maximal peak <italic>I</italic>
<sub>Na</sub> amplitudes appear considerably larger in hiPSC-CMs [<xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR37">37</xref>] than those reported for native human ventricular CMs [<xref ref-type="bibr" rid="CR38">38</xref>], whereas <italic>SCN5A</italic>/Na<sub>v</sub>1.5 expression levels have been reported to be lower in hiPSC-CMs as compared to adult CMs [<xref ref-type="bibr" rid="CR39">39</xref>]. Hence, the apparent larger <italic>I</italic>
<sub>Na</sub> density in hiPSC-CMs as compared to native CMs is likely due to experimental conditions (i.e., reduced extracellular Na<sup>+</sup> concentration used in adult human ventricular CMs studies) rather than an increased number of functional channels. Conversely, the low upstroke velocity (a measure of Na<sup>+</sup> channel availability) often observed in hiPSC-CMs does not necessarily reflect low <italic>I</italic>
<sub>Na</sub> density but is likely due to the fact that at more positive MDP, a proportion of Na<sup>+</sup> channels is inactivated and therefore not functionally available. Values for half-voltage dependence of (in)activation (V<sub>1/2</sub>), the voltage at which half channels are (in)activated, were found to be similar among the several control hiPSC-CMs lines analyzed in different studies (Table <xref ref-type="table" rid="Tab1">1</xref>) [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. However, <italic>V</italic>
<sub>1/2</sub> values of (in)activation are generally shifted towards more positive potentials in hiPSC-CMs as compared to the values reported for ventricular CMs isolated from healthy individuals [<xref ref-type="bibr" rid="CR38">38</xref>] (Table <xref ref-type="table" rid="Tab1">1</xref>). Similar to human adult CMs, Na<sup>+</sup> channels in hiPSC-CMs are sensitive to micromolar doses of the sodium channel blocker tetrodotoxin [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR41">41</xref>] (Table <xref ref-type="table" rid="Tab2">2</xref>). Thus, <italic>I</italic>
<sub>Na</sub> characteristics appear comparable between hiPSC-CMs and human adult CMs. Although the initial large inward <italic>I</italic>
<sub>Na</sub> that contributes to the AP upstroke is for the most part rapidly inactivated, a small fraction of the current (designated the late sodium current, <italic>I</italic>
<sub>NaL</sub>) persists throughout the duration of the AP plateau. Enhanced <italic>I</italic>
<sub>NaL</sub> is typically found during heart failure and long QT syndrome type 3 (LQT3, see “<xref ref-type="sec" rid="Sec22">Pharmacological Studies for Inherited Arrhythmia Syndromes Using hiPSC-CMs</xref>” section) [<xref ref-type="bibr" rid="CR42">42</xref>]. <italic>I</italic>
<sub>NaL</sub> in freshly isolated healthy human CMs is small [<xref ref-type="bibr" rid="CR38">38</xref>]; in some hiPSC-CMs studies, <italic>I</italic>
<sub>NaL</sub> was observed to be similarly small [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], while in other studies, it was reported to be absent [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p>
</sec>
<sec id="Sec7">
<title>Calcium Current (<italic>I</italic><sub>Ca</sub>)</title>
<p id="Par11">Two types of Ca<sup>2+</sup> channels are present in the human heart, the L-type and T-type channels, i.e., <italic>I</italic>
<sub>CaL</sub> and <italic>I</italic>
<sub>CaT</sub>. For hiPSC-CMs, the presence of <italic>I</italic>
<sub>CaT</sub> has been debated: <italic>I</italic>
<sub>CaT</sub> was reported in a subset of hiPSC-CMs in one study [<xref ref-type="bibr" rid="CR41">41</xref>], while in another, the current was not detected [<xref ref-type="bibr" rid="CR30">30</xref>]. Similarly, <italic>I</italic>
<sub>CaT</sub> is not functionally present in healthy human native ventricular CMs but is present in the human heart conduction system, where it plays a role in facilitation of pacemaker depolarization [<xref ref-type="bibr" rid="CR43">43</xref>]. <italic>I</italic>
<sub>CaL</sub> plays a crucial role in maintaining the plateau phase of the AP and in excitation–contraction coupling in cardiac cells. Several studies have shown the presence of a robust <italic>I</italic>
<sub>CaL</sub> in hiPSC-CMs [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. With the exception of the study of Veerman et al., [<xref ref-type="bibr" rid="CR33">33</xref>], <italic>I</italic>
<sub>CaL</sub> densities [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>] and mid-voltage inactivation values in hiPSC-CMs [<xref ref-type="bibr" rid="CR30">30</xref>] are similar to those described for adult ventricular CMs [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Voltage dependence of activation is generally shifted towards more negative potentials in hiPSC-CMs as compared to human native CMs (Table <xref ref-type="table" rid="Tab1">1</xref>), while time course of current inactivation, analyzed in only one study [<xref ref-type="bibr" rid="CR45">45</xref>], was similar to that reported in human ventricular CMs [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. The L-type Ca<sup>2+</sup> channel blocker nifedipine decreased <italic>I</italic>
<sub>CaL</sub> [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] and resulted in shortening of the AP in hiPSC-CMs with minimal effects on upstroke velocity [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Thus, hiPSC-CMs have robust <italic>I</italic>
<sub>CaL</sub> with characteristics close to that observed in adult human CMs.</p>
</sec>
<sec id="Sec8">
<title>Transient Outward Potassium Current (<italic>I</italic><sub>to1</sub>)</title>
<p id="Par12">Efflux of K<sup>+</sup> secondary to activation of the transient outward potassium current (<italic>I</italic>
<sub>to1</sub>) results in the relatively short-lasting repolarization phase 1 of the AP. A wide variation in peak current densities and kinetics has been reported for <italic>I</italic>
<sub>to1</sub> in both native ventricular CMs [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR49">49</xref>–<xref ref-type="bibr" rid="CR51">51</xref>] and hiPSC-CMs [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR52">52</xref>] (Table <xref ref-type="table" rid="Tab1">1</xref>), which can in part be explained by differences in experimental conditions. In addition, marked regional differences in density and kinetic properties of <italic>I</italic>
<sub>to1</sub> exist between subendocardial and subepicardial layers of human ventricular myocardium, contributing to the transmural electric gradient. In particular, subepicardial myocytes display increased <italic>I</italic>
<sub>to1</sub> density and faster recovery as compared to subendocardial CMs [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Only one study analyzed <italic>I</italic>
<sub>to1</sub> recovery from inactivation in hiPSC-CMs, which proved to be markedly slower than previously reported in human adult epicardial ventricular CMs but comparable to values reported for human adult endocardial CMs [<xref ref-type="bibr" rid="CR52">52</xref>]. In hiPSC-CMs with a relatively depolarized MDP, the functional relevance of <italic>I</italic>
<sub>to1</sub> may be limited, since a large proportion of the channels will be inactivated under these conditions. This, in combination with the slow recovery of the channel, which would further reduce <italic>I</italic>
<sub>to1</sub> availability, likely explains the less pronounced phase 1 of the AP in hiPSC-CMs [<xref ref-type="bibr" rid="CR52">52</xref>].</p>
</sec>
<sec id="Sec9">
<title>Slow and Rapid Delayed Rectifier Potassium Currents (<italic>I</italic><sub>Ks</sub> and <italic>I</italic><sub>Kr</sub>)</title>
<p id="Par13">The rapid component of the delayed rectifier potassium current (<italic>I</italic>
<sub>Kr</sub>) has been reported in hiPSC-CMs [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR53">53</xref>–<xref ref-type="bibr" rid="CR56">56</xref>], with most studies showing a maximal density similar to or higher than that observed in native human ventricular CMs [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>] (Table <xref ref-type="table" rid="Tab1">1</xref>). In line with this, blockade of <italic>I</italic>
<sub>Kr</sub> by E-4031 (Table <xref ref-type="table" rid="Tab2">2</xref>) in hiPSC-CMs resulted in a significant AP prolongation and induced early afterdepolarizations (EADs) [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Thus, <italic>I</italic>
<sub>Kr</sub> plays a prominent role in the repolarization phase of hiPSC-CMs AP. Moreover, mainly due to absence or low expression of <italic>I</italic>
<sub>K1</sub>, <italic>I</italic>
<sub>Kr</sub> plays an important role in the determination of the MDP in hiPSC-CMs [<xref ref-type="bibr" rid="CR53">53</xref>]. In native human ventricular CMs, the slow component of the delayed rectifier potassium current (<italic>I</italic>
<sub>Ks</sub>) was reported to be present in approximately half of the cells studied, with a maximal current density of 0.18 pA/pF [<xref ref-type="bibr" rid="CR60">60</xref>], a value similar to what was reported by Egashira et al. (~0.22 pA/pF) [<xref ref-type="bibr" rid="CR61">61</xref>] and Ma et al. (0.31 pA/pF) [<xref ref-type="bibr" rid="CR30">30</xref>] in hiPSC-CMs. In contrast, other studies showed higher values for <italic>I</italic>
<sub>Ks</sub> density in hiPSC-CMs [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR62">62</xref>] (Table <xref ref-type="table" rid="Tab1">1</xref>). This variability in current density may be partly explained by altered expression of the β-subunit KCNE1, as suggested by a study in human embryonic stem cell-derived CMs (hESC-CMs) [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
<p id="Par14">Studies on the functional relevance of <italic>I</italic>
<sub>Ks</sub> have demonstrated mixed results. In dog or non-diseased human ventricular CMs, <italic>I</italic>
<sub>Ks</sub> blockade with chromanol 293B, HMR-1556, and L-735,821 did not significantly prolong APD at baseline but only in the presence of β-adrenergic stimulation (enhancing <italic>I</italic>
<sub>Ks</sub> and accelerating its activation) or in the setting of decreased repolarization reserve (i.e., <italic>I</italic>
<sub>Kr</sub> blockade) [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. The conclusion that <italic>I</italic>
<sub>Ks</sub> does not play a role in repolarization under resting conditions has however been challenged by Towart et al. [<xref ref-type="bibr" rid="CR66">66</xref>] who found that JNJ303, an <italic>I</italic>
<sub>Ks</sub> inhibitor with enhanced potency, evoked torsades de pointes arrhythmias in anesthetized dogs [<xref ref-type="bibr" rid="CR66">66</xref>]. In hiPSC-CMs, Ma et al. showed that <italic>I</italic>
<sub>Ks</sub> blockade by chromanol 293B resulted only in minimal prolongation of the AP [<xref ref-type="bibr" rid="CR30">30</xref>]; on the other hand, it significantly prolonged field potential duration (reflecting the QT interval; see also “<xref ref-type="sec" rid="Sec19">Multi-Electrode Arrays</xref>” section) in a multicellular hiPSC-CMs preparation in another study [<xref ref-type="bibr" rid="CR61">61</xref>]. Upon β-adrenergic stimulation with isoprotenerol, <italic>I</italic>
<sub>Ks</sub> amplitude was increased in control hiPSC-CMs, and AP duration was reduced accordingly [<xref ref-type="bibr" rid="CR26">26</xref>]. In contrast, in the study of Zhang et al., AP duration was unaffected in control hiPSC-CMs after application of noradrenaline [<xref ref-type="bibr" rid="CR12">12</xref>]. Of note, patients carrying heterozygous or homozygous mutations in the <italic>KCNQ1</italic> gene encoding <italic>I</italic>
<sub>Ks</sub> show markedly prolonged QT intervals under resting conditions (see also “<xref ref-type="sec" rid="Sec24">Long QT Syndrome Type 1</xref>” section). Importantly, hiPSC-CMs from these patients display significant AP prolongation [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], suggesting a functional role for <italic>I</italic>
<sub>Ks</sub> in repolarization control in hiPSC-CMs.</p>
</sec>
<sec id="Sec10">
<title>Inward Rectifier Potassium Current (<italic>I</italic><sub>K1</sub>)</title>
<p id="Par15">The inward rectifier K<sup>+</sup> current (<italic>I</italic>
<sub>K1</sub>) is important for maintaining the RMP in atrial and ventricular CMs [<xref ref-type="bibr" rid="CR67">67</xref>]. In adult human CMs, <italic>I</italic>
<sub>K1</sub> density varies between 3.6 and 32.1 pA/pF, depending on the different experimental conditions [<xref ref-type="bibr" rid="CR68">68</xref>]. <italic>I</italic>
<sub>K1</sub> density in hiPSC-CMs [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR68">68</xref>] is considerably smaller, and <italic>KCNJ2</italic> mRNA expression (encoding the α-subunit of the channel) is correspondingly low [<xref ref-type="bibr" rid="CR39">39</xref>]. The small <italic>I</italic>
<sub>K1</sub> density in hiPSC-CMs likely contributes to the frequently observed spontaneous activity in these cells. Furthermore, the consequent depolarized RMP of hiPSC-CMs also significantly affects other AP characteristics, including upstroke velocity and duration. To overcome this limitation, various studies have artificially introduced <italic>I</italic>
<sub>K1</sub> into hiPSC-CMs, either by in silico injection or viral transfection (see “<xref ref-type="sec" rid="Sec21">Approaches for Improved Electrophysiological Measurements in hiPSC-CMs</xref>” section).</p>
</sec>
<sec id="Sec11">
<title>“Funny” Current (<italic>I</italic><sub>f</sub>)</title>
<p id="Par16">
<italic>I</italic>
<sub>f</sub> is an inward, depolarizing current activating at hyperpolarized membrane potentials. It is mediated by the family of the HCN channels (HCN1–4) with <italic>HCN4</italic> being the most abundant isoform underlying <italic>I</italic>
<sub>f</sub> in sinoatrial cells [<xref ref-type="bibr" rid="CR69">69</xref>]. The presence of <italic>I</italic>
<sub>f</sub> has also been demonstrated in human atrial CMs [<xref ref-type="bibr" rid="CR70">70</xref>] and in human ventricular CMs [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. A relatively large <italic>I</italic>
<sub>f</sub> density has been reported in hiPSC-CMs [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR48">48</xref>], which may be attributed to the fact that hiPSC-CMs express higher levels of the <italic>HCN4</italic> isoform as compared to adult human ventricular CMs [<xref ref-type="bibr" rid="CR39">39</xref>]. In the study of Ma et al., <italic>I</italic>
<sub>f</sub> in hiPSC-CMs was reported to be activated already at relatively depolarized membrane potentials (negative to −60 mV), suggesting that it may contribute to the spontaneous activity often observed in these cells [<xref ref-type="bibr" rid="CR30">30</xref>]. However, this observation was not confirmed in a recent paper of Zhang and colleagues [<xref ref-type="bibr" rid="CR48">48</xref>] where <italic>I</italic>
<sub>f</sub> activated at potentials negative to −80 mV; moreover, these authors demonstrated that application of ivabradine, a selective <italic>I</italic>
<sub>f</sub> blocker, had no effect on the spontaneous beating frequency in hiPSC-CMs.</p>
</sec>
</sec>
<sec id="Sec12">
<title>Intracellular Ca<sup>2+</sup> and Na<sup>+</sup> Homeostasis</title>
<p id="Par17">The intracellular Ca<sup>2+</sup> (Ca<sup>2+</sup>
<sub>i</sub>) transient which underlies the contraction of a myocyte is triggered by Ca<sup>2+</sup> influx through <italic>I</italic>
<sub>CaL</sub>, which results in release of Ca<sup>2+</sup> from the sarcoplasmic reticulum (SR) via ryanodine-2 (RyR2) channels (i.e., Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release). The subsequent decline of Ca<sup>2+</sup>
<sub>i</sub> (required for diastolic relaxation) occurs mainly through reuptake into the SR mediated by sarco/endoplasmic reticulum Ca<sup>2+</sup>-ATPase (SERCA) and through extrusion of Ca<sup>2+</sup> via the Na<sup>+</sup>-Ca<sup>2+</sup> exchanger (NCX) in the plasma membrane [<xref ref-type="bibr" rid="CR73">73</xref>]. Diastolic Ca<sup>2+</sup>
<sub>i</sub> is determined by this Ca<sup>2+</sup>
<sub>i</sub> decline and by the magnitude of “leak” of Ca<sup>2+</sup> from the SR through RyR2 channels [<xref ref-type="bibr" rid="CR74">74</xref>]. An additional mechanism for increased diastolic Ca<sup>2+</sup>
<sub>i</sub> is consequent to elevation of intracellular Na<sup>+</sup> (Na<sup>+</sup>
<sub>i</sub>) levels; the latter is controlled by a fine balance between Na<sup>+</sup> influx (through Na<sup>+</sup> channels, NCX, and Na<sup>+</sup>/H<sup>+</sup> exchanger) and Na<sup>+</sup> extrusion (via Na<sup>+</sup>/K<sup>+</sup>-ATPase) [<xref ref-type="bibr" rid="CR75">75</xref>]. An increase of Na<sup>+</sup>
<sub>i</sub> will result in intracellular Ca<sup>2+</sup> overload via enhanced reverse-mode NCX activity [<xref ref-type="bibr" rid="CR76">76</xref>]. While Ca<sup>2+</sup> is essential for cardiac contraction, increased diastolic Ca<sup>2+</sup>
<sub>i</sub> and/or spontaneous Ca<sup>2+</sup> release from the SR may set the stage for cardiac arrhythmias. Thus, Ca<sup>2+</sup>
<sub>i</sub> and Na<sup>+</sup>
<sub>i</sub> are tightly regulated within CMs, and their dysregulation may have profound pro-arrhythmic consequences.</p>
<p id="Par18">So far, only a few studies have investigated Ca<sup>2+</sup>
<sub>i</sub> and Na<sup>+</sup>
<sub>i</sub> in hiPSC-CMs. Key Ca<sup>2+</sup> handling proteins are expressed in hiPSC-CMs, and the presence of functional SR and RyR activity has been demonstrated [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR77">77</xref>–<xref ref-type="bibr" rid="CR79">79</xref>]. Due to limited access to freshly isolated healthy human ventricular CMs, Hwang et al. compared hiPSC-CMs with rabbit and mouse CMs [<xref ref-type="bibr" rid="CR44">44</xref>]. They found that Ca<sup>2+</sup>
<sub>i</sub> transients in hiPSC-CMs are largely similar to those in rabbit and mouse CMs, except for a much slower Ca<sup>2+</sup>
<sub>i</sub> transient rise and decay in hiPSC-CMs [<xref ref-type="bibr" rid="CR44">44</xref>]. The slower rise is likely the result of a poor coupling between Ca<sup>2+</sup> influx through <italic>I</italic>
<sub>CaL</sub> and SR Ca<sup>2+</sup> release through RyRs due to lack of t-tubuli in hiPSC-CMs. The slower Ca<sup>2+</sup>
<sub>i</sub> transient decay may be related to the immature state of hiPSC-CMs. Indeed, Ca<sup>2+</sup>
<sub>i</sub> transient decay became faster by prolongation of the time after induction of cardiac differentiation [<xref ref-type="bibr" rid="CR44">44</xref>]. The relative contribution of the Ca<sup>2+</sup>
<sub>i</sub> removal pathways, including SERCA and NCX, was not significantly different from adult rabbit CMs [<xref ref-type="bibr" rid="CR44">44</xref>]. Thus, these findings suggest both similarities and dissimilarities in Ca<sup>2+</sup>-handling between hiPSC-CMs and adult CMs.</p>
</sec>
</sec>
<sec id="Sec13">
<title>Electrophysiological Studies Using hiPSC-CMs: Technical Considerations</title>
<p id="Par19">A variety of invasive and non-invasive methods exists for the electrophysiological analysis of hiPSC-CMs, including patch clamp methodology and sharp electrode measurements, multi-electrode arrays (MEAs), and voltage-sensitive fluorescence (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). Each technique has specific strengths and limitations in hiPSC-CMs research as discussed in more detail below.</p>
<sec id="Sec14">
<title>Patch Clamp Technique</title>
<p id="Par20">The patch clamp technique is relatively labor intensive and requires skilled and experienced operators. Yet, it is considered the gold standard for electrophysiological research since it is the most informative method, allowing both the recording of membrane currents and AP parameters (Figs. <xref ref-type="fig" rid="Fig1">1</xref>b and <xref ref-type="fig" rid="Fig2">2</xref>a) [<xref ref-type="bibr" rid="CR80">80</xref>]. It entails gently pressing a relatively blunt glass pipette (2–4 MΩ) against a cell membrane after which suction is applied to obtain a high resistance, omega-shaped, seal. After gaining access to the cell, the “whole-cell patch clamp configuration” is obtained which allows for measurement of APs and membrane currents in “current” and “voltage” clamp, respectively. Patch clamp technique can be performed manually (positioning the pipettes with the help of micro-manipulators) or with the so-called automated patch clamp technique [<xref ref-type="bibr" rid="CR81">81</xref>–<xref ref-type="bibr" rid="CR83">83</xref>] (see “<xref ref-type="sec" rid="Sec17">Automated Patch Clamp</xref>” section).</p>
<sec id="Sec15">
<title>Current Clamp</title>
<p id="Par21">In the current clamp mode, the current injected through the patch pipette is controlled while the free-running membrane potential of the cell is recorded. Current clamp allows measurements of APs that may either occur spontaneously or in response to an injected stimulus current via the patch pipette. A population of hiPSC-CMs typically contains both spontaneous beating and quiescent cells. In most studies, spontaneously beating hiPSC-CMs are selected to measure APs, since beating cells are considered to be CMs. However, spontaneously beating hiPSC-CMs are frequently depolarized and have a diastolic (phase 4) depolarization phase, which further depolarizes the membrane potential to around −40 mV prior to AP onset. Such a large depolarization inactivates various membrane currents such as <italic>I</italic>
<sub>Na</sub>, and <italic>I</italic>
<sub>to1</sub>, and increases the importance of <italic>I</italic>
<sub>Ks</sub> and <italic>I</italic>
<sub>Kr</sub> in setting the diastolic membrane potential [<xref ref-type="bibr" rid="CR84">84</xref>]. To partially overcome these limitations, in some studies quiescent hiPSC-CMs able to contract on field stimulation are specifically selected for analysis [<xref ref-type="bibr" rid="CR31">31</xref>]. However, selecting cells this way is technically challenging and time consuming.</p>
<p id="Par22">To obtain whole-cell configuration, both the ruptured or perforated “whole-cell” patch clamp methodology may be used. Although access to the cell is typically better in ruptured patch, Ca<sup>2+</sup>-buffers (such as EGTA) are often added to the pipette solution when using this technique, which may modulate intracellular Ca<sup>2+</sup> cycling and consequently affect cardiac contraction, AP morphology, and automaticity in hiPSC-CMs via Ca<sup>2+</sup>-sensitive ion channels and exchangers [<xref ref-type="bibr" rid="CR85">85</xref>]. This is less of an issue when employing the perforated patch technique, which also provides more stable AP waveforms over time. In hiPSC-CMs studies, the current clamp technique can be used to measure APs from single cells as well as from clusters [<xref ref-type="bibr" rid="CR86">86</xref>]. However, hiPSC-CMs clusters may contain a mixed population of “atrial-like,” “ventricular-like,” and “nodal-like” CMs, as well as cells which are not cardiomyocytes, and coupling between hiPSC-CMs and the latter may affect the AP depolarization and repolarization phase. These considerations need to be taken into account.</p>
</sec>
<sec id="Sec16">
<title>Voltage Clamp</title>
<p id="Par23">In voltage clamp mode, the membrane potential is held at a set voltage level through a feedback circuit patch clamp amplifier, which allows the recording of the net membrane current at a given membrane potential. Applying dedicated voltage clamp protocols, ion current densities (defined as current divided by cell size) and various physiological properties, i.e., voltage dependency of (in)activation, recovery from inactivation, slow inactivation, and speed of current (in)activation and deactivation can be studied in single cells under carefully controlled conditions (see also “<xref ref-type="sec" rid="Sec3">Electrophysiological Characteristics of hiPSC-CMs</xref>” section).</p>
</sec>
<sec id="Sec17">
<title>Automated Patch Clamp</title>
<p id="Par24">While the manual patch clamp technique (as described in “<xref ref-type="sec" rid="Sec15">Current Clamp</xref>” and “<xref ref-type="sec" rid="Sec16">Voltage Clamp</xref>” sections) is regarded as the gold standard for electrophysiological studies, experimental procedures can be complex and time consuming, resulting in low throughput. In contrast, automated patch, by allowing multiple recordings in parallel, can increase data throughput 10- to 100-fold depending on the ion channel under investigation and the platform used [<xref ref-type="bibr" rid="CR16">16</xref>]. With automated patch clamp, the traditional glass pipette is replaced by an aperture at the bottom of a well through which an applied negative pressure patches the cell membrane. While this allows the automatization of the patch clamp process, this automated technique requires high quality, high density, and homogenous single-cell suspensions [<xref ref-type="bibr" rid="CR81">81</xref>–<xref ref-type="bibr" rid="CR83">83</xref>], which can be challenging since hiPSC-CMs are relatively expensive to produce on a large scale and highly sensitive to enzymatic dissociation into single cells. Moreover, the automated patch technique does not allow for selection of cells to be measured, i.e., hiPSC-derived cardiomyocytes vs. fibroblasts, or hiPSC-CMs labeled with GFP following viral transfection or other genetic approaches. Ma et al. compared manual and automated patch in hiPSC-CMs and reported a variable success rates for planar automated patch clamp analysis, with acceptable recordings obtained in ~50% of measurements; however, they observed differences in current density and cell capacitance between automated and manually patched cells [<xref ref-type="bibr" rid="CR30">30</xref>]. Some of these observed differences may be consequent to the hiPSC-CMs dissociation protocols used for manual vs. automated patch clamp experiments; for the latter, trypsin is often used which may impact on recording quality by affecting membrane proteins [<xref ref-type="bibr" rid="CR87">87</xref>]. Using an alternative two-step dissociation protocol (consisting of trypsin dissociation, reseeding at a low density, and reharvesting by gentle dissociation with accutase), Rajamohan and colleagues were able to increase the number of successful automated recordings [<xref ref-type="bibr" rid="CR88">88</xref>]. Thus, electrophysiological analysis of hiPSC-CMs using high-throughput automated patch approach is feasible [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR88">88</xref>], but certain limitations need to be considered.</p>
</sec>
</sec>
<sec id="Sec18">
<title>Sharp Microelectrode Measurements</title>
<p id="Par25">The intracellular sharp microelectrode technique is a traditional and well-established tool to measure accurate voltage or electrical currents passing through the membrane. In contrast to the patch clamp technique, cells or tissue are impaled with one or two sharp glass microelectrodes (&gt;30 MΩ), which are filled with a rather non-physiological, high K<sup>+</sup> solution. Two electrodes are needed to perform voltage clamp experiments, but one electrode is enough to perform current clamp measurements. The insertion of the microelectrodes into cells and/or tissue may result in some damage and consequent membrane depolarization; smaller cells (i.e., hiPSC-CMs) are more sensitive to this potential limitation. The sharp electrode technique is often used to record APs from hiPSC-CMs clusters and hence is associated with the potential limitation of mixed cell types within these clusters.</p>
</sec>
<sec id="Sec19">
<title>Multi-Electrode Arrays</title>
<p id="Par26">While the intracellular patch clamp and sharp microelectrode methodology generates high-quality AP and membrane current data, it is considered laborious and time consuming with multiple technical issues potentially preventing successful recordings. In addition to automated patch, non-invasive measurements of extracellular signals with MEAs are increasingly used in hiPSC-CMs research. From the electrical signals (field potentials, FPs), beating frequency and field potential duration (FPD), considered to resemble QT interval and AP duration, can be determined (Fig. <xref ref-type="fig" rid="Fig2">2</xref>b). MEAs allow long-term measurements of FPs from clusters and monolayers of hiPSC-CMs and are often used to test (new) compounds or genetic defects, particularly in relation to their effect on AP repolarization and QT interval [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. MEA measurements are often performed in spontaneous beating clusters and monolayers and few MEA setups have implemented methods for electrical stimulation. Thus, the majority of measurements are performed on multicellular tissue which is not paced at a fixed frequency, and hence compounds which alter cycle length may consequently affect field potential characteristics indirectly. To normalize for differences in beating rates, QT intervals are typically corrected using the Bazett or Fridericia formula. While this type of correction is efficient in patients, it may not be accurate in such in vitro conditions [<xref ref-type="bibr" rid="CR14">14</xref>]<italic>.</italic> Moreover, in MEA experiments, it is difficult to distinguish between direct effects of compounds and genetic defects on FPDs or indirect effects through alterations of other AP parameters such as MDP, since information on the latter is not easily obtained using this technique [<xref ref-type="bibr" rid="CR90">90</xref>]. In addition, the various cell types and coupling between CMs in multicellular preparations may dilute precise determination of effects. Moreover, hiPSC-CMs measured with MEAs are less sensitive to compounds than single cells [<xref ref-type="bibr" rid="CR59">59</xref>], but this is a general finding in multicellular preparations. Finally, MEAs do not allow for assessment of biophysical parameters of specific ion currents, a prerequisite when assessing potential (novel) therapeutic approaches for inherited arrhythmic disorders. On the other hand, local activation times can be determined at each electrode within the MEA, allowing for generation of detailed activation maps and conduction velocity measurements. Conduction velocity in hiPSC-CMs monolayers is, however, relatively slow (10–20 cm/s compared to 60 cm/s in adult human left ventricle) [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>], likely due to differences in <italic>I</italic>
<sub>Na</sub> distribution and availability, connexin distribution, and morphology and geometry of hiPSC-CMs (see [<xref ref-type="bibr" rid="CR15">15</xref>]).</p>
</sec>
<sec id="Sec20">
<title>Fluorescence Measurements</title>
<p id="Par27">Another non-invasive method to assess electrical activity in a high-throughput manner is through voltage-sensitive fluorescence. For this, hiPSC-CMs can be loaded for instance with the voltage-sensitive dye di-4-ANEPPS [<xref ref-type="bibr" rid="CR93">93</xref>]. Voltage fluorescence can be used to quantify conduction velocities in multicellular preparations, as well as AP parameters in isolated hiPSC-CMs or clusters. For multicellular preparations and clusters, the potential associated disadvantages of effects of coupling, changes in MDP, and spontaneous activity mentioned above should be taken into account. In addition, motion artifacts need to be prevented to obtain stable signals, and therefore an inhibitor of myosin-actin interaction is often used, such as 2,3-butanedione monoxime (BDM). Both BDM and the voltage-sensitive dye, however, may have impact on basic electrical properties. In hiPSC-CMs, calcium handling properties can additionally be studied using calcium-sensitive dyes such as Fluo-2AM or Indo-1AM [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. However, fluorescent dyes can be phototoxic and are therefore not suitable for prolonged recordings. Alternatively, genetically engineered hiPSC-CMs expressing a voltage (ArcLight) fluorescent indicator can be used, which has the advantage that specific hiPSC-CMs cell types can specifically be measured by use of specific promotors for over-expression [<xref ref-type="bibr" rid="CR94">94</xref>]. While fluorescent approaches may be implemented for initial high-throughput assessment of compounds (screening for novel drugs and/or cardiac safety assays) [<xref ref-type="bibr" rid="CR95">95</xref>], they do not provide information on ion current characteristics. Furthermore, the lack of reference values (i.e., 0 mV level) is an important drawback since small variations in MDP may not be detected, yet may still importantly impact on ion channel availability and AP characteristics as recently discussed in more detail by others [<xref ref-type="bibr" rid="CR96">96</xref>–<xref ref-type="bibr" rid="CR98">98</xref>].</p>
</sec>
<sec id="Sec21">
<title>Approaches for Improved Electrophysiological Measurements in hiPSC-CMs</title>
<p id="Par28">All techniques described above can be employed for pharmacological studies in hiPSC-CMs research, keeping in mind the advantages and disadvantages of the various approaches. One of the disadvantages is that hiPSC-CMs clusters and monolayers may contain non-cardiomyocytes which influence electrophysiological properties [<xref ref-type="bibr" rid="CR99">99</xref>]. However, these days, various methods exist to highly purify the population of hiPSC-CMs, including the puromycin and blasticidin selection method [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR99">99</xref>], lactate treatment [<xref ref-type="bibr" rid="CR100">100</xref>], and fluorescence-based cell sorting [<xref ref-type="bibr" rid="CR101">101</xref>]. Many research laboratories are applying approaches aimed at enhancing the structural and functional maturation of hiPSC-CMs. For example, increasing time in culture, medium additives, electrical stimulation, mechanical stretch and/or load, use of polymers, and 3D culture have been shown to improve sarcomeric organization, intracellular calcium handling, contractility, and electrophysiological parameters including MDP and upstroke velocity (see [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]). Furthermore, some limitations are inherent to the lack of <italic>I</italic>
<sub>K1</sub> in hiPSC-CMs resulting in spontaneous activity, depolarized membrane potentials, and difficulties in pacing the cells at the required frequency. To overcome this, a number of groups have employed artificial enhancement of <italic>I</italic>
<sub>K1</sub> density through either viral over-expression of Kir2.1, the channel conducting <italic>I</italic>
<sub>K1</sub> [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>], or by injection of an in silico <italic>I</italic>
<sub>K1</sub> with kinetics of Kir2.1 [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR104">104</xref>] (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a–c). Over-expression of Kir2.1 in hESC-CMs [<xref ref-type="bibr" rid="CR102">102</xref>] abolished cell automaticity, rendering AP characteristics similar to those of adult CMs. Nevertheless, these cells continued to exhibit immature Ca<sup>2+</sup> handling properties and reduced expression of contractile proteins was reported [<xref ref-type="bibr" rid="CR102">102</xref>]. In contrast, forced Kir2.1 expression in hiPSC-CMs improved both AP and Ca<sup>2+</sup> transient properties [<xref ref-type="bibr" rid="CR103">103</xref>]. This approach may be particularly useful for MEAs and voltage-sensitive fluorescence measurements, although variability in Kir2.1 over-expression levels may enhance heterogeneity. The second approach entails increasing <italic>I</italic>
<sub>K1</sub> through in silico injection of a current with similar properties using the dynamic clamp technique [<xref ref-type="bibr" rid="CR105">105</xref>]. Bett and colleagues were the first to employ this “electronic expression” of <italic>I</italic>
<sub>K1</sub> in hiPSC-CMs experiments [<xref ref-type="bibr" rid="CR104">104</xref>]. More recently, our group investigated the in silico injection of varying magnitudes of <italic>I</italic>
<sub>K1</sub> in hiPSC-CMs at physiological temperatures [<xref ref-type="bibr" rid="CR68">68</xref>] (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a–c). In both studies, enhanced <italic>I</italic>
<sub>K1</sub> induced a more physiological and stable RMP, a ventricular-like AP morphology, and increased AP upstroke velocity [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. Hence, in silico <italic>I</italic>
<sub>K1</sub> injection constitutes a robust tool for improved AP measurements in hiPSC-CMs.<fig id="Fig3"><label>Fig. 3</label><caption><p>Effect of <italic>I</italic>
<sub>K1</sub> injection on maximal diastolic potential (<italic>MDP</italic>) and maximal upstroke velocity (<italic>dV</italic>/<italic>dt</italic>
<sub><italic>max</italic></sub>) in hiPSC-CMs. <bold>a</bold> Representative example of action potential traces recorded from hiPSC-CMs upon injection of increasing magnitudes of simulated <italic>I</italic>
<sub>K1</sub> using dynamic clamp. Impact of <italic>I</italic>
<sub>K1</sub> injection at different amplitudes on MDP and dV/dt<sub>max</sub> is shown in panels <bold>b</bold> and <bold>c</bold>, respectively (*<italic>p</italic> &lt; 0.05). Figure reproduced from [<xref ref-type="bibr" rid="CR68">68</xref>]</p></caption><graphic id="MO3" xlink:href="10557_2017_6735_Fig3_HTML"></graphic></fig>
</p>
</sec>
</sec>
<sec id="Sec22">
<title>Pharmacological Studies for Inherited Arrhythmia Syndromes Using hiPSC-CMs</title>
<p id="Par29">Research into the genetic defects underlying inherited arrhythmia syndromes has increased knowledge on the underlying pro-arrhythmic mechanisms and triggering events. In some cases, this has provided insight into optimal therapeutic strategies for preventing the occurrence of arrhythmias and/or their triggering events [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, for many syndromes, clinical management is still hindered by insufficient knowledge on mutation- and/or patient-specific disease expressivity and treatment efficacy, necessitating development of individualized therapeutic strategies. In vitro and animal models have been used to develop and screen novel pharmacological treatments for inherited arrhythmia disorders. However, these models are not always predictive of drug efficacy in patients, potentially leading to compounds being inappropriately rejected or further developed without success. In this respect, hiPSC-CMs may offer an attractive alternative. Several studies have already shown that hiPSC-CMs can recapitulate the disease phenotype of numerous inherited arrhythmic disorders in vitro (for review, see [<xref ref-type="bibr" rid="CR29">29</xref>]). The next crucial step involves investigating whether hiPSC-CMs are valid models of cardiac arrhythmia that respond appropriately to clinically relevant pharmacology.</p>
<sec id="Sec23">
<title>Long QT Syndrome</title>
<p id="Par30">Long QT syndrome (LQTS) is an inherited cardiac disorder characterized by QT interval prolongation and increased risk for sudden death due to ventricular tachyarrhythmias, in particular torsades de pointes. At cellular level, LQTS is characterized by AP prolongation and increased incidence of EADs, which can reach the threshold and trigger ventricular arrhythmias. LQTS has been linked to mutations in 15 genes. Long QT syndrome type 1 (LQT1) is the most common form of LQTS, accounting for ≈35% of cases and is associated with loss-of-function mutations in the <italic>KCNQ1</italic> gene, which encodes for the α-subunit of the channel conducting <italic>I</italic>
<sub>Ks</sub>. Long QT syndrome type 2 (LQT2), accounting for 30% of cases, arises from loss-of-function mutations in <italic>KNCH2</italic> (also known as hERG), encoding <italic>I</italic>
<sub>Kr</sub>. Gain-of-function mutations in <italic>SCN5A</italic>, the gene encoding for the α-subunit of the cardiac sodium channel Na<sub>v</sub>1.5, are linked to LQT3, which accounts for ≈10% of cases. Overall, these three genes account for ≈90% of genotype-positive LQTS patients [<xref ref-type="bibr" rid="CR1">1</xref>]. LQT1 responds well to beta-blockade, but for LQT2 and LQT3, development of additional therapeutic strategies may improve patient care.</p>
<sec id="Sec24">
<title>Long QT Syndrome Type 1</title>
<p id="Par31">The first report showing that hiPSCs could model a cardiac channelopathy was the study of Moretti et al. [<xref ref-type="bibr" rid="CR26">26</xref>], where hiPSC-CMs from a LQT1 patient (carrying the <italic>KCNQ1</italic>-R190Q mutation) recapitulated the electrical phenotype of the disease; patch clamp analysis revealed AP prolongation and decreased <italic>I</italic>
<sub>Ks</sub> in LQT1 hiPSC-CMs as compared to control hiPSC-CMs. Moreover, β-adrenergic stimulation with isoprotenerol exacerbated AP prolongation and facilitated development of EADs in spontaneously beating LQT1 hiPSC-CMs; pre-treatment with propranolol blunted these isoproterenol-induced effects [<xref ref-type="bibr" rid="CR26">26</xref>]. These observations are in line with the fact that fatal arrhythmias in LQT1 patients are typically precipitated by increased sympathetic tone and are prevented by beta-blocker therapy. In another study modeling LQT1 [<xref ref-type="bibr" rid="CR61">61</xref>], the <italic>I</italic>
<sub>Ks</sub> blocker chromanol 293B significantly prolonged FPD in control cells but not in LQT1 hiPSC-CMs, suggesting <italic>I</italic>
<sub>Ks</sub> dysfunction. Administration of the <italic>I</italic>
<sub>Kr</sub> blocker E-4031 prolonged FPD in both control and LQT1 hiPSC-CMs but induced frequent severe arrhythmia only in LQT1 hiPSC-CMs [<xref ref-type="bibr" rid="CR61">61</xref>], indicating reduced repolarization reserve in the latter. Moreover, isoproterenol induced EADs and pro-arrhythmia only in LQT1 hiPSC-CMs, and these were prevented by the beta-blocker propranolol [<xref ref-type="bibr" rid="CR61">61</xref>]. It has to be noted, however, that in this study, only MEAs were performed and no single-cell AP measurements. In their study, Ma et al. showed that the ML277 compound, a selective <italic>I</italic>
<sub>Ks</sub> activator recently identified, was able to (partly) reverse the decreased <italic>I</italic>
<sub>Ks</sub> and AP prolongation (measured at a relatively depolarized MDP of around −60 mV) in hiPSC-CMs from an LQT1 patient with a deletion mutation in <italic>KCNQ1</italic> [<xref ref-type="bibr" rid="CR62">62</xref>]. While LQT1 is transmitted in an autosomal dominant manner, homozygous or compound heterozygous mutations in <italic>KCNQ1</italic> or the β-subunit <italic>KCNE1</italic> cause the Jervell and Lange-Nielsen syndrome (JLNS), which has a autosomal recessive pattern of inheritance and is associated with severe life-threatening cardiac arrhythmias, a high risk of sudden death due to ventricular tachycardia, and congenital bilateral deafness [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. In the study of Zhang et al. [<xref ref-type="bibr" rid="CR12">12</xref>], hiPSC-CMs from a JNLS patient displayed increased AP duration which was further exacerbated by noradrenaline; this effect was partially reversed by treatment with the β-blocker propranolol. Furthermore, JNLS hiPSC-CMs were more susceptible to arrhythmias when exposed to cisapride, a gastrointestinal drug with known pro-arrhythmic effects through blockade of <italic>I</italic>
<sub>Kr</sub>. While beta-blockade is only partially effective in most JNLS patients, in their study, Zhang and colleagues did observe beneficial effects of propranolol on AP duration [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
</sec>
<sec id="Sec25">
<title>Long QT Syndrome Type 2</title>
<p id="Par32">The first report showing the capability of hiPSC-CMs to recapitulate the clinical phenotype of LQT2 was the study of Itzhaki and colleagues, who observed decreased <italic>I</italic>
<sub>Kr</sub>, AP prolongation, and marked pro-arrhythmic features (i.e., EADs and triggered activity) in hiPSC-CMs derived from LQT2 patient carrying the <italic>KCNH2</italic>-A614V mutation [<xref ref-type="bibr" rid="CR55">55</xref>]. Pinacidil, a K<sub>ATP</sub>-channel opener, and nifedipine, an L-type Ca<sup>2+</sup> channel blocker, caused a significant shortening of both APD and corrected FPD; importantly, pinacidil and nifedipine application completely abolished all EADs and triggered arrhythmias in LQT2 hiPSC-CMs [<xref ref-type="bibr" rid="CR55">55</xref>]. The potential anti-arrhythmic efficacy of the late Na<sup>+</sup> current blocker ranolazine was also evaluated. Interestingly, ranolazine application did not significantly alter APD or cFPD, likely due to its nonspecific blocking effect on different ion channels. Nevertheless, ranolazine suppressed triggered activity and EADs in LQT2 hiPSC-CMs [<xref ref-type="bibr" rid="CR55">55</xref>]. However, the APs in this study showed a depolarized MDP of around −55 mV and a low AP upstroke velocity, indicating relatively immature cells. Furthermore, information on (changes in) MDP was not provided in the drug studies. In the study of Matsa et al., the effect of several compounds was tested in control and LQT2 hiPSC-CMs (<italic>KCNH2</italic>-A561T) [<xref ref-type="bibr" rid="CR59">59</xref>]. Exposure to E-4031 provoked AP/FPD prolongation in control and LQT2 hiPSC-CMs, with EADs observed only in the mutant cells. In contrast to control CMs, LQT2 hiPSC-CMs also developed EADs when challenged with the β-adrenoreceptor agonist isoprenaline. This effect was reversed by the β-blockers propranolol and nadolol; the latter was also successfully employed as therapy in the patient [<xref ref-type="bibr" rid="CR59">59</xref>]. In the same study, two experimental potassium channel enhancers were also tested: nicorandil, an <italic>I</italic>
<sub>KATP</sub> channel opener, and PD-118057, an <italic>I</italic>
<sub>Kr</sub> channel enhancer. In LQT2 hiPSC-CMs, both nicorandil and PD-118057 shortened APD by ~18%, with nicorandil also abolishing spontaneously occurring EADs [<xref ref-type="bibr" rid="CR59">59</xref>]. AP duration was shortened by a further 29.5% (to 58.1%) when combining nicorandil and PD-118057. However, administration of these compounds in combination with isoprenaline induced EADs, suggesting that LQT2 patients treated with potassium channel openers could still be at risk of developing cardiac arrhythmias in the setting of β-adrenoreceptor activation, including exercise. Since these pro-arrhythmic features were prevented by nadolol and propranolol, a treatment strategy combining potassium channel openers with β-blockers was proposed by the authors [<xref ref-type="bibr" rid="CR59">59</xref>]. It has to be noted, however, that in this particular study, spontaneously beating hiPSC-CMs were used for AP measurements, and no data on MDP was provided. In another study, Lahti et al. [<xref ref-type="bibr" rid="CR54">54</xref>] tested several compounds with known QT prolongation effects in <italic>KCNH2</italic>-R176W hiPSC-CMs using MEAs. The hERG blocker E-4031 induced EADs in control hiPSC-CMs and even more frequently in LQT2 hiPSC-CMs. In contrast, application of sotalol, an anti-arrhythmic drug with both β-blocker and class III activity, elicited EADs only in LQT2 hiPSC-CMs. No increased arrhythmogenicity was observed with erythromycin or cisapride in either control or LQT2 hiPSC-CMs [<xref ref-type="bibr" rid="CR54">54</xref>]. Of note, in this study, a decreased <italic>I</italic>
<sub>Kr</sub> was found in hiPSC-CMs obtained from an LQT2 patient carrying this particular mutation (R176W), in line with the clinical phenotype. In contrast, when the same mutation was co-expressed with wild type channels in HEK293 cells, no reduction in <italic>I</italic>
<sub>Kr</sub> was observed [<xref ref-type="bibr" rid="CR107">107</xref>], underlining the relevance of hiPSC-CMs as disease models. Spencer et al. furthermore showed that the increased AP duration observed in hiPSC-CMs from an LQT2 patient carrying the <italic>KCNH2</italic>-A422T mutation was abbreviated by exposure to the L-type Ca<sup>2+</sup> channel blocker nifedipine [<xref ref-type="bibr" rid="CR78">78</xref>]. In addition to assessing the effects of established therapeutic approaches, hiPSC-CMs may also be used for investigating novel compounds. In their study, Sala et al. [<xref ref-type="bibr" rid="CR14">14</xref>] made use of a series of isogenically matched, diseased, and genetically engineered hiPSC-CMs from patients to test a novel allosteric hERG modulator for treating congenital LQTS, drug-induced LQTS, or a combination of the two. By slowing <italic>I</italic>
<sub>Kr</sub> deactivation and positively shifting its inactivation, the small molecule LUF7346 effectively rescued all of these conditions, demonstrating in a human system that this approach may be useful to treat inherited and drug-induced LQTS [<xref ref-type="bibr" rid="CR14">14</xref>] (Fig. <xref ref-type="fig" rid="Fig4">4</xref>). Similarly, Mehta et al. demonstrated reversal of the LQT2 phenotype (including increased <italic>I</italic>
<sub>Kr</sub>, AP shortening at stable but relatively depolarized RMP, and reduced arrhythmogenic events) in <italic>KCNH2</italic>-C1682T hiPSC-CMs by the small molecule <italic>N</italic>-[<italic>N</italic>-(<italic>N</italic>-acetyl-<sc>l</sc>-leucyl)-<sc>l</sc>-leucyl]-<sc>l</sc>-norleucine (ALLN) [<xref ref-type="bibr" rid="CR56">56</xref>]. This compound was shown to act through restoration of membrane trafficking of hERG, comprising a potential novel therapeutic approach [<xref ref-type="bibr" rid="CR56">56</xref>]. Taken together, these studies (although in some cases potentially involving relatively immature cells) demonstrate the potential applicability of hiPSC-CMs for pharmacological studies in LQT2.<fig id="Fig4"><label>Fig. 4</label><caption><p>Effect of the hERG allosteric modulator LUF7346 on field potential <italic>(FP)</italic> and action potential (<italic>AP</italic>) duration in LQT2 hiPSC-CMs. <bold>a</bold> Representative FP traces showing the effect of increasing concentrations of LUF7346 on FP duration measured in LQT2 hiPSC-CMs carrying the N996I mutation (LQT2<sup>N996I</sup>). <bold>b</bold> Representative AP traces from LQT2<sup>N996I</sup> hiPSC-CMs under baseline conditions (Tyrode) and after application of increasing concentrations of LUF7346 (color-code panels are shown in the insets). LUF7346 reduced FP and AP duration in LQT2<sup>N996I</sup> hiPSC-CMs. Figure modified from [<xref ref-type="bibr" rid="CR14">14</xref>]</p></caption><graphic id="MO4" xlink:href="10557_2017_6735_Fig4_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec26">
<title>Long QT Syndrome Type 3</title>
<p id="Par33">In LQT3, <italic>I</italic>
<sub>Na</sub> inactivation is compromised or channel reopening occurs, leading to <italic>I</italic>
<sub>NaL</sub> which persists throughout the entire AP and ultimately causes AP prolongation and pro-arrhythmia. Some drugs are known to preferentially inhibit this <italic>I</italic>
<sub>NaL</sub>, including mexiletine and ranolazine. In hiPSC-CMs from a patient with a de novo LQT3 mutation (<italic>SCN5A-</italic>F1473C) and a polymorphism (K897T) in <italic>KCNH2</italic>, analysis of the biophysical properties of <italic>I</italic>
<sub>Na</sub> and <italic>I</italic>
<sub>Kr</sub> demonstrated that increased <italic>I</italic>
<sub>NaL</sub> was responsible for the pro-arrhythmic phenotype and that the latter was not influenced by the <italic>KCNH2</italic> polymorphism [<xref ref-type="bibr" rid="CR40">40</xref>]. In the hiPSC-CMs of the patient, increasing the stimulation rate resulted in a 50% decrease in <italic>I</italic>
<sub>NaL</sub>; when mexiletine was added, <italic>I</italic>
<sub>NaL</sub> was further reduced. This improved <italic>I</italic>
<sub>NaL</sub> block at the higher stimulation rate was associated with only a modest reduction in peak <italic>I</italic>
<sub>Na</sub>, ensuring minimal detrimental impact on conduction. Addition of a second <italic>I</italic>
<sub>Na</sub> blocker, flecainide, did not induce a significant further increase in <italic>I</italic>
<sub>NaL</sub> block at higher stimulation frequency but further reduced peak <italic>I</italic>
<sub>Na.</sub> Consistent with these in vitro findings, the most effective arrhythmia control in the patient was achieved by increasing atrial pacing via ICD and by mexiletine treatment [<xref ref-type="bibr" rid="CR40">40</xref>]. Importantly, while previous studies in heterologous expression systems had reported differing effects of <italic>KCNH2</italic>-K897T on channel function, in hiPSC-CMs, this variant did not impact on anti-arrhythmic drug efficacy. In another study, mexiletine was found to shorten APD and FPD in LQT3 hiPSC-CMs and antagonized EADs in a dose-dependent manner [<xref ref-type="bibr" rid="CR108">108</xref>]. Moreover, the <italic>I</italic>
<sub>NaL</sub> blockers phenytoin and ranolazine also reduced APDs/FPDs in the same model (<italic>SCN5A</italic>-R1644H), with no effect on control hiPSC-CMs. These findings were in agreement with the pharmacological response profile of the underlying patient carrying the mutation and of other patients from the same family [<xref ref-type="bibr" rid="CR108">108</xref>]. Similarly, Ma et al. showed that mexiletine reduced <italic>I</italic>
<sub>NaL</sub> and APD in <italic>SCN5A</italic>-V1763M hiPSC-CMs, with little effect on control cells [<xref ref-type="bibr" rid="CR35">35</xref>]. We recently investigated hiPSC-CMs from a patient carrying the <italic>SCN5A</italic>-1795insD mutation associated with both a gain (LQT3) and a loss (Brugada syndrome, conduction disease) of Na<sup>+</sup> channel function. The selective <italic>I</italic>
<sub>NaL</sub> blocker GS967 was able to reduce the prolonged AP duration (measured with in silico injection of <italic>I</italic>
<sub>K1</sub>) induced by the increased <italic>I</italic>
<sub>NaL</sub> associated with the mutation in these hiPSC-CMs [<xref ref-type="bibr" rid="CR37">37</xref>] (Fig. <xref ref-type="fig" rid="Fig5">5</xref>a). Despite the pre-existent reduced peak <italic>I</italic>
<sub>Na</sub> consequent to the mutation, GS967 only caused a minimal reduction in AP upstroke velocity. Importantly, hiPSC-CMs displayed a similar response to GS967 as adult, freshly isolated CMs from mice harboring the mouse homolog of the mutation <italic>Scn5a</italic>-1798insD [<xref ref-type="bibr" rid="CR37">37</xref>] (Fig. <xref ref-type="fig" rid="Fig5">5</xref>b). In line with the small effect observed on AP upstroke velocity, GS967 did not affect ventricular conduction velocity in isolated wild type or <italic>Scn5a</italic>-1798insD hearts [<xref ref-type="bibr" rid="CR37">37</xref>]. While these observations strengthen the use of hiPSC-CMs as a valid model for pharmacological studies in inherited sodium channelopathy, complete similarity in results was not observed, since murine <italic>Scn5a</italic>-1798insD CMs displayed EADs and delayed afterdepolarizations (DADs) which were reduced by GS967, but no such pro-arrhythmic features were observed in <italic>SCN5A</italic>-1795insD hiPSC-CMs [<xref ref-type="bibr" rid="CR37">37</xref>]. This may be due to the relative short APs measured in our hiPSC-CMs, with repolarizing currents suppressing the development of EADs even despite the increased <italic>I</italic>
<sub>NaL</sub>.<fig id="Fig5"><label>Fig. 5</label><caption><p>Comparable effect of the late sodium current blocker GS967 in <italic>SCN5A</italic>-1795insD<sup>+/−</sup> hiPSC-CMs and <italic>Scn5a</italic>-1798insD<sup>+/−</sup> murine cardiomyocytes. <bold>a</bold>, <bold>b</bold> Representative action potential (<italic>AP</italic>) traces (<italic>left panel</italic>) and average data for AP duration at 90% repolarization (APD<sub>90</sub>, <italic>right panel</italic>) in <italic>SCN5A</italic>-1795insD<sup>+/−</sup> hiPSC-CMs (<bold>a</bold>) and in <italic>Scn5a</italic>-1798insD<sup>+/−</sup> cardiomyocytes (<bold>b</bold>) before and after application of GS967. GS967 was able to reduce AP duration in both models. *<italic>p</italic> &lt; 0.05. Reproduced from [<xref ref-type="bibr" rid="CR37">37</xref>], with permission</p></caption><graphic id="MO5" xlink:href="10557_2017_6735_Fig5_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec27">
<title>Long QT Syndrome Type 8 (Timothy Syndrome)</title>
<p id="Par34">A single amino acid substitution (G406R) in <italic>CACNA1C</italic>, the gene encoding for the L-type Ca<sup>2+</sup> channel, is the cause of Timothy syndrome (long QT syndrome type 8 (LQT8), the most severe variant of LQTS because of its high mortality rate. Besides a marked QT interval prolongation and severe ventricular arrhythmia, LQT8 presents with congenital heart defects, AV block, syndactyly, autism, malignant hypoglycemia, and an abnormal immune system [<xref ref-type="bibr" rid="CR1">1</xref>]<italic>.</italic> In 2011, Yazawa and colleagues showed that hiPSC-CMs from LQT8 patients recapitulated the electrical phenotype of the disease (prolonged APD, DADs, and altered Ca<sup>2+</sup> transients) [<xref ref-type="bibr" rid="CR27">27</xref>]. The experimental drug roscovitine, which alters <italic>I</italic>
<sub>CaL</sub> inactivation, reduced AP duration, restored the irregular Ca<sup>2+</sup> transient, and decreased the frequency of abnormal depolarizations in LQT8 hiPSC-CMs [<xref ref-type="bibr" rid="CR27">27</xref>]. However, spontaneously beating cells were used for AP measurements, and therefore a contributory role for alterations in frequency cannot be completely ruled out. Nevertheless, the findings were confirmed in a more recent study employing simultaneous recording of APs and calcium transients in LQT8 hiPSC-CMs using genetically encoded fluorescent indicators [<xref ref-type="bibr" rid="CR109">109</xref>].</p>
</sec>
</sec>
<sec id="Sec28">
<title>Brugada Syndrome</title>
<p id="Par35">Brugada syndrome (BrS) is an inherited disorder characterized by ventricular arrhythmias and sudden cardiac death occurring in otherwise healthy individuals at a relatively young age (<italic>&lt;</italic>40 years), typically during conditions of high vagal tone (i.e., sleep). On ECG analysis, a typical pattern is observed comprising ST-segment elevation in the right-precordial leads V1–V3 [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. Mechanistically, both depolarization and repolarization abnormalities may be involved, with predominant involvement of the right ventricular outflow tract. In about 20% of BrS patients, a mutation in <italic>SCN5A</italic> has been identified. In general, <italic>SCN5A</italic> mutations associated with BrS are “loss-of-function” mutations, leading to reduced Na<sup>+</sup> channel availability, either through decreased membrane surface channel expression or through altered channel gating properties [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. Mutations in other genes have also been sporadically found, and BrS may in fact have a more complex genetic basis than previously thought. In BrS patients at high risk of (recurrent) ventricular tachyarrhythmias, implantation of an ICD should be considered, and pharmacological options are limited. Only few studies so far have recapitulated the BrS phenotype in hiPSC-CMs [<xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR33">33</xref>], and only one study has tested potential pharmacological interventions. Kosmidis et al. recapitulated the phenotype of two <italic>SCN5A</italic> nonsense mutations (W156X and R1638X) which lead to premature termination of translation and production of truncated proteins [<xref ref-type="bibr" rid="CR32">32</xref>]. As expected, BrS hiPSC-CMs presented reduced AP upstroke velocity (despite similar MDP) and decreased peak <italic>I</italic>
<sub>Na</sub> as compared to control hiPSC-CMs. In these hiPSC-CMs, the effects of two compounds were investigated, i.e., gentamicin and PTC124, both of which are considered capable of promoting translational readthrough of premature stop codons and hence restoring expression of the full-length, non-truncated protein. While the authors confirmed the readthrough efficacy of the two drugs in HEK293 cells, they did not observe rescue of the electrophysiological phenotype in these BrS hiPSC-CMs [<xref ref-type="bibr" rid="CR32">32</xref>]. The authors concluded that the effects of the compounds may have been too small to have any functional impact in the setting of the heterozygous BrS mutations.</p>
</sec>
<sec id="Sec29">
<title>Catecholaminergic Polymorphic Ventricular Tachycardia</title>
<p id="Par36">Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by stress and exercise-induced ventricular arrhythmias (in particular, bidirectional VT) in young patients with structurally normal hearts. Autosomal dominant mutations in <italic>RyR2</italic>, the gene encoding for the ryanodine receptor type 2 (CPVT1) or recessive mutations in <italic>CASQ2</italic>, the gene encoding for calsequestrin 2 (CPVT2) are the most common mutations linked to CPVT, resulting in spontaneous Ca<sup>2+</sup> release from the SR and consequent DADs, triggered activity, and ventricular tachyarrhythmias [<xref ref-type="bibr" rid="CR112">112</xref>]. The first study modeling CPVT using hiPSCs was performed by Itzaki et al., where CPVT1 hiPSC-CMs carrying the <italic>RYR2</italic>-M4109R mutation showed increased DADs incidence and Ca<sup>2+</sup> transient irregularities as compared to control hiPSC-CMs, which were further exacerbated by β-adrenergic stimulation [<xref ref-type="bibr" rid="CR113">113</xref>]. Both flecainide, a sodium channel blocker, and thapsigargin, eliminated DADs in this CPVT1 hiPSC-CMs model [<xref ref-type="bibr" rid="CR113">113</xref>]. Similar beneficial effects of flecainide were also more recently observed in <italic>RyR</italic>-L3741P hiPSC-CMs, where it improved calcium homeostasis and reduced DADs incidence; clinical efficacy of flecainide was subsequently observed in the mutation carrier [<xref ref-type="bibr" rid="CR114">114</xref>]. In the study by Jung et al. [<xref ref-type="bibr" rid="CR115">115</xref>], dantrolene, an inhibitor of sarcoplasmic Ca<sup>2+</sup> release, which is effective on malignant hyperthermia and is commonly used in the treatment of CPVT patients, restored normal Ca<sup>2+</sup> handling properties and rescued the arrhythmogenic phenotype in hiPSC-CMs from a CPVT1 patient carrying the S406L mutation in <italic>RyR2</italic>. In a successive study, the antiarrhythmic efficacy of dantrolene during exercise testing was assessed in six patients carrying various <italic>RyR2</italic> mutations [<xref ref-type="bibr" rid="CR116">116</xref>]. Dantrolene reduced the number of premature ventricular complexes (PVCs) on average by 74% in four patients with N-terminal mutations or mutations in the cytosolic region of the RyR2 protein, while it had no effect in two patients with mutations in or near the transmembrane domain. hiPSC-CMs from the patients replicated these individual drug responses. In hiPSC-CMs with <italic>RyR2</italic> mutations in the N-terminal or cytosolic region, dantrolene abolished the majority of Ca<sup>2+</sup> transient abnormalities, while it had minimal effect on Ca<sup>2+</sup> transients in CMs carrying mutations in or near the transmembrane domain [<xref ref-type="bibr" rid="CR116">116</xref>]. In another hiPSC-CMs model of CPVT1 (<italic>RyR2</italic>-G2311A), the CamKII inhibitor KN-93 abolished isoprotenerol-induced DADs, thereby rescuing the arrhythmogenic phenotype [<xref ref-type="bibr" rid="CR117">117</xref>]. Of note, results obtained in hiPSC-CMs were in agreement with those previously acquired in a <italic>RyR2</italic> knock-in CPVT mouse model [<xref ref-type="bibr" rid="CR117">117</xref>]. More recently, Sasaki et al. studied <italic>RyR2</italic>-I4587V hiPSC-CMs and showed that the compound S107, a 1,4-benzothiazepine derivate that stabilizes the closed state of RyR channels (thereby preventing Ca<sup>2+</sup> leak) by strengthening the interaction between RyR and calstabin, decreased the incidence of isoproterenol-induced DADs [<xref ref-type="bibr" rid="CR118">118</xref>]. Apart from CPVT1, two recent studies have also investigated hiPSC-CMs model of CPVT2. Lodola et al. observed isoproterenol-induced DADs and, less frequently, triggered activity in hiPSC-CMs carrying the p.G112+5X mutation in the <italic>CASQ2</italic> gene [<xref ref-type="bibr" rid="CR119">119</xref>]. Over-expression of wild type human <italic>CASQ2</italic> by adeno-associated virus-mediated delivery restored calcium dysregulation and significantly reduced DADs incidence [<xref ref-type="bibr" rid="CR119">119</xref>]. More recently, Haron-Khun and colleagues investigated the potential involvement of SK4 calcium-activated potassium channels in CPVT2 hiPSC-CMs and mice. The selective SK4 blocker TRAM-34 significantly reduced isoproterenol-induced DADs in <italic>CASQ2</italic>-D307H hiPSC-CMs and freshly isolated, adult ventricular CMs from mice carrying the same mutation [<xref ref-type="bibr" rid="CR120">120</xref>]. Moreover, TRAM-34 also demonstrated in vivo anti-arrhythmic effects in <italic>Casq2</italic>-D307H knock-in mice during rest and after exercise [<xref ref-type="bibr" rid="CR120">120</xref>]. Finally, homozygous mutations in <italic>TECRL</italic>, the gene encoding for the trans-2,3-enoyl-CoA reductase like protein, are associated with inherited arrhythmias characterized by clinical features of both LQTS and CPVT [<xref ref-type="bibr" rid="CR79">79</xref>]. hiPSC-CMs generated from a patient carrying the homozygous splice site mutation c.331+1G&gt;A (Fig. <xref ref-type="fig" rid="Fig6">6</xref>a) in <italic>TECRL</italic> (TECRL<sub>HOM</sub> hiPSC-CMs) revealed increased diastolic Ca<sup>2+</sup> concentrations, smaller Ca<sup>2+</sup> transient amplitudes, slower Ca<sup>2+</sup> rise and decay, as well as prolonged APD compared to hiPSC-CMs generated from his heterozygous but clinically asymptomatic father (TECRL<sub>HET</sub>), and a healthy individual (control, CTRL) [<xref ref-type="bibr" rid="CR79">79</xref>] (Fig. <xref ref-type="fig" rid="Fig6">6</xref>b, c). Increased triggered activity based on the occurrence of delayed afterdepolarizations observed in TECRL<sub>HOM</sub> hiPSC-CMs following exposure to noradrenaline was reduced by treatment with flecainide [<xref ref-type="bibr" rid="CR79">79</xref>] (Fig. <xref ref-type="fig" rid="Fig6">6</xref>d). Overall, these studies underline the validity of hiPSC-CMs as CPVT disease model and indicate its potential for identifying (novel) therapeutic strategies.<fig id="Fig6"><label>Fig. 6</label><caption><p>Electrophysiological characteristics of a homozygous mutation in <italic>TECRL</italic>, the gene encoding for the trans-2,3-enoyl-CoA reductase like protein. <bold>a</bold> Example of ventricular tachycardia recorded by the implantable cardioverter defibrillator (<italic>ICD</italic>) in a patient carrying the homozygous splice site mutation c.331+1G&gt;A in <italic>TECRL.</italic>
<bold>b</bold>, <bold>c</bold> Representative calcium transient (<bold>b</bold>) and action potential (<bold>c</bold>) traces recorded in control (<italic>CTRL</italic>), heterozygous (<italic>HET</italic>), and homozygous (<italic>HOM</italic>) hiPSC-CMs carrying the <italic>TECRL</italic> mutation c.331+1G&gt;A. The mutation causes a significant increase in diastolic calcium concentrations (<bold>b</bold>) and prolongation of action potential duration (<bold>c</bold>). <bold>d</bold> Addition of 5 μM flecainide (<italic>Flec</italic>) decreased the susceptibility to triggered activity in HOM hiPSC-CMs challenged with noradrenaline (<italic>NA</italic>). Reproduced from [<xref ref-type="bibr" rid="CR79">79</xref>]</p></caption><graphic id="MO6" xlink:href="10557_2017_6735_Fig6_HTML"></graphic></fig>
</p>
</sec>
</sec>
<sec id="Sec30">
<title>Conclusions and Perspectives</title>
<p id="Par37">Despite their potential limitations due to their intrinsic differences compared to adult CMs, hiPSC-CMs are increasingly recognized as valid disease models and tools for pharmacological research. They represent a platform with potential for investigating the molecular pharmacology of ion channel mutations expressed in more complex genetic backgrounds and can provide unique insight into therapeutic approaches for mutation- and/or individual-specific disease management. Studies employing hiPSC-CMs obtained from patients with inherited arrhythmia syndromes have demonstrated clear similarities between in vitro effects of pharmacological interventions and their reported clinical efficacy. This is further confirmed by our recent work demonstrating good correlation between effects of a late <italic>I</italic>
<sub>Na</sub> inhibitor in both hiPSC-CMs and mouse CMs carrying the same <italic>SCN5A</italic> mutation and similar observations by others in CPVT1 mice and hiPSC-CMs [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. However, the available data on the validity of hiPSC-CMs as models of inherited arrhythmia syndromes is still limited, and effects of pharmacological interventions may vary depending on the gene, the mutation, the individual, as well as technical factors related to hiPSC-CMs use. The availability of novel techniques to genetically modify hiPSC-CMs (including CRISPR-Cas9) will likely accelerate the number of mutations to be studied in the near future and facilitate investigations into mutation-specific therapy. hiPSC-CMs may also be employed to explore other non-pharmacological, gene-based therapeutics, such as allele-specific RNA interference aimed at specifically silencing expression of the allele containing the mutation, without interfering with the normal, non-mutated mRNA [<xref ref-type="bibr" rid="CR121">121</xref>]. Moreover, the application of automated patch clamp in hiPSC-CMs disease models will facilitate high-throughput drug screens aimed at identifying novel therapeutic compounds, in addition to cardiac safety screening.</p>
<p id="Par38">Given the expanding spectrum of inherited disorders associated with cardiac arrhythmias, hiPSC-CMs may also be employed for investigating arrhythmogenic mechanisms and potential therapeutic strategies for diseases such as familial atrial fibrillation, conduction disease, arrhythmogenic (right ventricular) cardiomyopathy, and hypertrophic cardiomyopathy. By studying electrophysiological characteristics of hiPSC-CMs from patients with inherited arrhythmia syndromes without an identified causal mutation, the underlying (pro-arrhythmic) disease mechanisms may be identified [<xref ref-type="bibr" rid="CR33">33</xref>]. Conversely, correcting an identified putative mutation in patient-derived hiPSC-CMs enables establishment of causality [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Moreover, comparing hiPSC-CMs from patients carrying the same genetic defect but displaying varying disease expressivity and/or severity may provide insight into the modulatory role of genetic modifiers. Finally, using CRISPR-Cas9 technology, genetic variants may be introduced in hiPSC-CMs lines and their impact on electrophysiological and potential pro-arrhythmic characteristics investigated [<xref ref-type="bibr" rid="CR12">12</xref>], either in isolation or in combination with a known disease-causing mutation.</p>
<p id="Par39">Despite their promising use in this wide range of applications, certain limitations intrinsic to hiPSC-CMs need to be considered and addressed. In particular, the issue of immaturity remains an important matter, and techniques aimed at enhancing maturity are continuously being developed and refined, including exposure to electrical stimulation, application of mechanical strain, and culturing hiPSC-CMs in three-dimensional tissue configuration. In addition, artificial enhancement of <italic>I</italic>
<sub>K1</sub> density facilitates accurate assessment of AP parameters. Improved definition and selection of hiPSC-CMs subtype (i.e., atrial, ventricular, Purkinje, nodal) will furthermore allow investigation of disease mechanisms and therapeutic efficacy in a cell type-specific manner. These developments are expected to further strengthen the validity of hiPSC-CMs as models of inherited arrhythmia syndromes as well as other disease entities and their applicability in (future) development of disease-, mutation-, and patient-specific therapies.</p>
</sec>
</body>
<back>
<notes notes-type="COI-statement">
<title>Compliance with Ethical Standards</title>
<sec id="FPar1">
<title>Funding</title>
<p id="Par40">This work was funded in part by a Priority Medicines Rare Diseases and Orphan Drugs grant (PM-Rare, 113303006) from The Netherlands Organization for Health Research and Development (ZonMw) and an Innovational Research Incentives Scheme Vidi grant from ZonMw (grant no. 91714371, to Dr. Remme).</p>
</sec>
<sec id="FPar2">
<title>Conflict of Interest</title>
<p id="Par41">Simona Casini declares that she has no conflict of interest, Arie O. Verkerk declares that he has no conflict of interest, and Carol Ann Remme has previously received a research grant from Gilead Sciences.</p>
</sec>
<sec id="FPar3">
<title>Ethical Approval</title>
<p id="Par42">This article does not contain any studies with human participants or animals performed by any of the authors.</p>
</sec>
<sec id="FPar4">
<title>Informed Consent Statement</title>
<p id="Par43">Not applicable.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bezzina</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Lahrouchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Priori</surname>
<given-names>SG</given-names>
</name>
</person-group>
<article-title>Genetics of sudden cardiac death</article-title>
<source/>Circ Res
          <year>2015</year>
<volume>116</volume>
<fpage>1919</fpage>
<lpage>1936</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.304030</pub-id>
<pub-id pub-id-type="pmid">26044248</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abriel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rougier</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Jalife</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Ion channel macromolecular complexes in cardiomyocytes: roles in sudden cardiac death</article-title>
<source/>Circ Res
          <year>2015</year>
<volume>116</volume>
<fpage>1971</fpage>
<lpage>1988</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305017</pub-id>
<pub-id pub-id-type="pmid">26044251</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olde Nordkamp</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Postema</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Knops</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>van Dijk</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Limpens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications</article-title>
<source/>Heart Rhythm
          <year>2016</year>
<volume>13</volume>
<fpage>443</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.1016/j.hrthm.2015.09.010</pub-id>
<pub-id pub-id-type="pmid">26385533</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Priori</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Horie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Behr</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Berul</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes</article-title>
<source/>Heart Rhythm
          <year>2013</year>
<volume>10</volume>
<fpage>e85</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1016/j.hrthm.2013.07.021</pub-id>
<pub-id pub-id-type="pmid">23916535</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Koopmann</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Le Scouarnec</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ingram</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans</article-title>
<source/>J Clin Invest
          <year>2008</year>
<volume>118</volume>
<fpage>2260</fpage>
<lpage>2268</lpage>
<pub-id pub-id-type="pmid">18464934</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stroud</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Atack</surname>
<given-names>TC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Striking in vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro</article-title>
<source/>Circulation
          <year>2011</year>
<volume>124</volume>
<fpage>1001</fpage>
<lpage>1011</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.987248</pub-id>
<pub-id pub-id-type="pmid">21824921</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nerbonne</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kass</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Molecular physiology of cardiac repolarization</article-title>
<source/>Physiol Rev
          <year>2005</year>
<volume>85</volume>
<fpage>1205</fpage>
<lpage>1253</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00002.2005</pub-id>
<pub-id pub-id-type="pmid">16183911</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</article-title>
<source/>Cell
          <year>2006</year>
<volume>126</volume>
<fpage>663</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.07.024</pub-id>
<pub-id pub-id-type="pmid">16904174</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ohnuki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Narita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ichisaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tomoda</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title>
<source/>Cell
          <year>2007</year>
<volume>131</volume>
<fpage>861</fpage>
<lpage>872</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.11.019</pub-id>
<pub-id pub-id-type="pmid">18035408</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burridge</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming</article-title>
<source/>Cell Stem Cell
          <year>2012</year>
<volume>10</volume>
<fpage>16</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2011.12.013</pub-id>
<pub-id pub-id-type="pmid">22226352</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Macadangdang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Laflamme</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening</article-title>
<source/>Biotechnol Adv
          <year>2017</year>
<volume>35</volume>
<fpage>77</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.biotechadv.2016.12.002</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>D'Aniello</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Verkerk</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Wrobel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ward-van Oostwaard</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2014</year>
<volume>111</volume>
<fpage>E5383</fpage>
<lpage>E5392</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1419553111</pub-id>
<pub-id pub-id-type="pmid">25453094</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Casini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>D'Aniello</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ward-van Oostwaard</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome</article-title>
<source/>EMBO J
          <year>2013</year>
<volume>32</volume>
<fpage>3161</fpage>
<lpage>3175</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2013.240</pub-id>
<pub-id pub-id-type="pmid">24213244</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sala</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ward-van Oostwaard</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Veldhoven</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Moretti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Laugwitz</surname>
<given-names>KL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells</article-title>
<source/>EMBO molecular medicine
          <year>2016</year>
<volume>8</volume>
<fpage>1065</fpage>
<lpage>1081</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201606260</pub-id>
<pub-id pub-id-type="pmid">27470144</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veerman</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Kosmidis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mummery</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Casini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Verkerk</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Bellin</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem?</article-title>
<source/>Stem Cells Dev
          <year>2015</year>
<volume>24</volume>
<fpage>1035</fpage>
<lpage>1052</lpage>
<pub-id pub-id-type="doi">10.1089/scd.2014.0533</pub-id>
<pub-id pub-id-type="pmid">25583389</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<mixed-citation publication-type="other">Denning C, Borgdorff V, Crutchley J, Firth KS, George V, Kalra S, et al. Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform. Biochim Biophys Acta. 2016;1863:1728–48.</mixed-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Soerens</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Koonce</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Palecek</surname>
<given-names>SP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional cardiomyocytes derived from human induced pluripotent stem cells</article-title>
<source/>Circ Res
          <year>2009</year>
<volume>104</volume>
<fpage>e30</fpage>
<lpage>e41</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.192237</pub-id>
<pub-id pub-id-type="pmid">19213953</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dick</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rajamohan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ronksley</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Denning</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening</article-title>
<source/>Biochem Soc Trans
          <year>2010</year>
<volume>38</volume>
<fpage>1037</fpage>
<lpage>1045</lpage>
<pub-id pub-id-type="doi">10.1042/BST0381037</pub-id>
<pub-id pub-id-type="pmid">20659000</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barad</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zeevi-Levin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shick</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shtrichman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lorber</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to beta-adrenergic stimulation</article-title>
<source/>J Cell Mol Med
          <year>2012</year>
<volume>16</volume>
<fpage>468</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1111/j.1582-4934.2011.01476.x</pub-id>
<pub-id pub-id-type="pmid">22050625</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathur</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Loskill</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jeeawoody</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>KE</given-names>
</name>
</person-group>
<article-title>In vitro cardiac tissue models: current status and future prospects</article-title>
<source/>Adv Drug Deliv Rev
          <year>2016</year>
<volume>96</volume>
<fpage>203</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1016/j.addr.2015.09.011</pub-id>
<pub-id pub-id-type="pmid">26428618</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nunes</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Miklas</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aschar-Sobbi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Nat Methods
          <year>2013</year>
<volume>10</volume>
<fpage>781</fpage>
<lpage>787</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.2524</pub-id>
<pub-id pub-id-type="pmid">23793239</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lian</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hazeltine</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Azarin</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2012</year>
<volume>109</volume>
<fpage>E1848</fpage>
<lpage>E1857</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1200250109</pub-id>
<pub-id pub-id-type="pmid">22645348</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burridge</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Matsa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>ZC</given-names>
</name>
<name>
<surname>Churko</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>AD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemically defined generation of human cardiomyocytes</article-title>
<source/>Nat Methods
          <year>2014</year>
<volume>11</volume>
<fpage>855</fpage>
<lpage>860</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.2999</pub-id>
<pub-id pub-id-type="pmid">24930130</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devalla</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Schwach</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Milnes</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>El-Haou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology</article-title>
<source/>EMBO molecular medicine
          <year>2015</year>
<volume>7</volume>
<fpage>394</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201404757</pub-id>
<pub-id pub-id-type="pmid">25700171</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Protze</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nussinovitch</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Ohana</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Backx</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Gepstein</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker</article-title>
<source/>Nat Biotechnol
          <year>2017</year>
<volume>35</volume>
<fpage>56</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3745</pub-id>
<pub-id pub-id-type="pmid">27941801</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bellin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Welling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Bott-Flugel</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Patient-specific induced pluripotent stem-cell models for long-QT syndrome</article-title>
<source/>N Engl J Med
          <year>2010</year>
<volume>363</volume>
<fpage>1397</fpage>
<lpage>1409</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa0908679</pub-id>
<pub-id pub-id-type="pmid">20660394</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yazawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hsueh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pasca</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hallmayer</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome</article-title>
<source/>Nature
          <year>2011</year>
<volume>471</volume>
<fpage>230</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1038/nature09855</pub-id>
<pub-id pub-id-type="pmid">21307850</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbuti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Benzoni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Campostrini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dell'Era</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Human derived cardiomyocytes: a decade of knowledge after the discovery of induced pluripotent stem cells</article-title>
<source/>Dev Dyn
          <year>2016</year>
<volume>245</volume>
<fpage>1145</fpage>
<lpage>1158</lpage>
<pub-id pub-id-type="doi">10.1002/dvdy.24455</pub-id>
<pub-id pub-id-type="pmid">27599668</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoekstra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mummery</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Bezzina</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Verkerk</surname>
<given-names>AO</given-names>
</name>
</person-group>
<article-title>Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias</article-title>
<source/>Front Physiol
          <year>2012</year>
<volume>3</volume>
<fpage>346</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2012.00346</pub-id>
<pub-id pub-id-type="pmid">23015789</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fiene</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Anson</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Kamp</surname>
<given-names>TJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents</article-title>
<source/>Am J Physiol Heart Circ Physiol
          <year>2011</year>
<volume>301</volume>
<fpage>H2006</fpage>
<lpage>H2017</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00694.2011</pub-id>
<pub-id pub-id-type="pmid">21890694</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Casini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>van den Berg</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Hoekstra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Remme</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Dambrot</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease</article-title>
<source/>Circulation
          <year>2012</year>
<volume>125</volume>
<fpage>3079</fpage>
<lpage>3091</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.066092</pub-id>
<pub-id pub-id-type="pmid">22647976</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<mixed-citation publication-type="other">Kosmidis G, Veerman CC, Casini S, Verkerk AO, van de Pas S, Bellin M, et al. Readthrough-promoting drugs gentamicin and PTC124 fail to rescue Nav1.5 function of human-induced pluripotent stem cell-derived cardiomyocytes carrying nonsense mutations in the sodium channel gene SCN5A. Circ Arrhythm Electrophysiol. 2016;9:e004227</mixed-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<mixed-citation publication-type="other">Veerman CC, Mengarelli I, Guan K, Stauske M, Barc J, Tan HL<italic>, et al.</italic> hiPSC-derived cardiomyocytes from Brugada Syndrome patients without identified mutations do not exhibit clear cellular electrophysiological abnormalities. Sci Rep 2016;6:30967.</mixed-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KS</given-names>
</name>
</person-group>
<article-title>Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Toxicol Appl Pharmacol
          <year>2016</year>
<volume>296</volume>
<fpage>42</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/j.taap.2016.01.015</pub-id>
<pub-id pub-id-type="pmid">26821276</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sahib</surname>
<given-names>NB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells</article-title>
<source/>Int J Cardiol
          <year>2013</year>
<volume>168</volume>
<fpage>5277</fpage>
<lpage>5286</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijcard.2013.08.015</pub-id>
<pub-id pub-id-type="pmid">23998552</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatima</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaifeng</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dittmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Linke</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0083005</pub-id>
<pub-id pub-id-type="pmid">24349418</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Portero</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Casini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoekstra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Verkerk</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Mengarelli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Belardinelli</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/− and human SCN5A-1795insD+/− iPSC-derived cardiomyocytes</article-title>
<source/>Cardiovasc Res
          <year>2017</year>
<volume>113</volume>
<fpage>829</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvx077</pub-id>
<pub-id pub-id-type="pmid">28430892</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valdivia</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Foell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Haworth</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased late sodium current in myocytes from a canine heart failure model and from failing human heart</article-title>
<source/>J Mol Cell Cardiol
          <year>2005</year>
<volume>38</volume>
<fpage>475</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2004.12.012</pub-id>
<pub-id pub-id-type="pmid">15733907</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sanchez-Freire</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity</article-title>
<source/>Circulation
          <year>2013</year>
<volume>127</volume>
<fpage>1677</fpage>
<lpage>1691</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.001883</pub-id>
<pub-id pub-id-type="pmid">23519760</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terrenoire</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Pass</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>JT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics</article-title>
<source/>J Gen Physiol
          <year>2013</year>
<volume>141</volume>
<fpage>61</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1085/jgp.201210899</pub-id>
<pub-id pub-id-type="pmid">23277474</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivashchenko</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Pipes</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Lozinskaya</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xiaoping</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Needle</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype</article-title>
<source/>Am J Physiol Heart Circ Physiol
          <year>2013</year>
<volume>305</volume>
<fpage>H913</fpage>
<lpage>H922</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00819.2012</pub-id>
<pub-id pub-id-type="pmid">23832699</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Remme</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>Late sodium current inhibition in acquired and inherited ventricular (dys)function and arrhythmias</article-title>
<source/>Cardiovasc Drugs Ther
          <year>2013</year>
<volume>27</volume>
<fpage>91</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1007/s10557-012-6433-x</pub-id>
<pub-id pub-id-type="pmid">23292167</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ono</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Cardiac T-type Ca(2+) channels in the heart</article-title>
<source/>J Mol Cell Cardiol
          <year>2010</year>
<volume>48</volume>
<fpage>65</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2009.08.021</pub-id>
<pub-id pub-id-type="pmid">19729018</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kryshtal</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Feaster</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Sanchez-Freire</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kamp</surname>
<given-names>TJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories</article-title>
<source/>J Mol Cell Cardiol
          <year>2015</year>
<volume>85</volume>
<fpage>79</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.05.003</pub-id>
<pub-id pub-id-type="pmid">25982839</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Haviland</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Saric</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fatima</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hescheler</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects</article-title>
<source/>Cell Calcium
          <year>2013</year>
<volume>54</volume>
<fpage>57</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceca.2013.04.004</pub-id>
<pub-id pub-id-type="pmid">23684427</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magyar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Iost</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kortvely</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Banyasz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Virag</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Szigligeti</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of endothelin-1 on calcium and potassium currents in undiseased human ventricular myocytes</article-title>
<source/>Pflugers Arch
          <year>2000</year>
<volume>441</volume>
<fpage>144</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1007/s004240000400</pub-id>
<pub-id pub-id-type="pmid">11205054</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mewes</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ravens</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>L-type calcium currents of human myocytes from ventricle of non-failing and failing hearts and from atrium</article-title>
<source/>J Mol Cell Cardiol
          <year>1994</year>
<volume>26</volume>
<fpage>1307</fpage>
<lpage>1320</lpage>
<pub-id pub-id-type="doi">10.1006/jmcc.1994.1149</pub-id>
<pub-id pub-id-type="pmid">7869391</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<mixed-citation publication-type="other">Zhang X-H, Wei H, Å ariÄ‡ T, Hescheler Jr, Cleemann L, Morad M. Regionally diverse mitochondrial calcium signaling regulates spontaneous pacing in developing cardiomyocytes. Cell Calcium 2015;57:321–336.</mixed-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wettwer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Amos</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Posival</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ravens</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin</article-title>
<source/>Circ Res
          <year>1994</year>
<volume>75</volume>
<fpage>473</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1161/01.RES.75.3.473</pub-id>
<pub-id pub-id-type="pmid">8062421</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nabauer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beuckelmann</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Uberfuhr</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Steinbeck</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle</article-title>
<source/>Circulation
          <year>1996</year>
<volume>93</volume>
<fpage>168</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.93.1.168</pub-id>
<pub-id pub-id-type="pmid">8616924</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akar</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Deschenes</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Armoundas</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Piacentino</surname>
<given-names>V</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Houser</surname>
<given-names>SR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic differences in transient outward K+ current of human and canine ventricular myocytes: insights into molecular composition of ventricular I<sub>to</sub></article-title>
<source/>Am J Physiol Heart Circ Physiol
          <year>2004</year>
<volume>286</volume>
<fpage>H602</fpage>
<lpage>H609</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00673.2003</pub-id>
<pub-id pub-id-type="pmid">14527940</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cordeiro</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Nesterenko</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Sicouri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goodrow</surname>
<given-names>RJ</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Treat</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Desai</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification and characterization of a transient outward K+ current in human induced pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>J Mol Cell Cardiol
          <year>2013</year>
<volume>60</volume>
<fpage>36</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.03.014</pub-id>
<pub-id pub-id-type="pmid">23542310</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doss</surname>
<given-names>MX</given-names>
</name>
<name>
<surname>Di Diego</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Goodrow</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cordeiro</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Nesterenko</surname>
<given-names>VV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr)</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0040288</pub-id>
<pub-id pub-id-type="pmid">22815737</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lahti</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Kujala</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Koivisto</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Pekkanen-Mattila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kerkela</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture</article-title>
<source/>Dis Model Mech
          <year>2012</year>
<volume>5</volume>
<fpage>220</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.008409</pub-id>
<pub-id pub-id-type="pmid">22052944</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itzhaki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Maizels</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Zwi-Dantsis</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Caspi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Winterstern</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modelling the long QT syndrome with induced pluripotent stem cells</article-title>
<source/>Nature
          <year>2011</year>
<volume>471</volume>
<fpage>225</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="doi">10.1038/nature09747</pub-id>
<pub-id pub-id-type="pmid">21240260</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sequiera</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Ramachandra</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Sudibyo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes</article-title>
<source/>Cardiovasc Res
          <year>2014</year>
<volume>102</volume>
<fpage>497</fpage>
<lpage>506</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvu060</pub-id>
<pub-id pub-id-type="pmid">24623279</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iost</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Virag</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Opincariu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Szecsi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Varro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>JG</given-names>
</name>
</person-group>
<article-title>Delayed rectifier potassium current in undiseased human ventricular myocytes</article-title>
<source/>Cardiovasc Res
          <year>1998</year>
<volume>40</volume>
<fpage>508</fpage>
<lpage>515</lpage>
<pub-id pub-id-type="doi">10.1016/S0008-6363(98)00204-1</pub-id>
<pub-id pub-id-type="pmid">10070491</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<mixed-citation publication-type="other">Jost N, Acsai K, Horvath B, Banyasz T, Baczko I, Bitay M, et al. Contribution of I<sub>Kr</sub> and I<sub>K1</sub> to ventricular repolarization in canine and human myocytes: is there any influence of action potential duration? Basic Res Cardiol. 2009;104:33–41.</mixed-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rajamohan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mellor</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Staniforth</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation</article-title>
<source/>Eur Heart J
          <year>2011</year>
<volume>32</volume>
<fpage>952</fpage>
<lpage>962</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehr073</pub-id>
<pub-id pub-id-type="pmid">21367833</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virag</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Iost</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Opincariu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Szolnoky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Szecsi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bogats</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The slow component of the delayed rectifier potassium current in undiseased human ventricular myocytes</article-title>
<source/>Cardiovasc Res
          <year>2001</year>
<volume>49</volume>
<fpage>790</fpage>
<lpage>797</lpage>
<pub-id pub-id-type="doi">10.1016/S0008-6363(00)00306-0</pub-id>
<pub-id pub-id-type="pmid">11230978</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egashira</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yuasa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aizawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yamakawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matsuhashi</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disease characterization using LQTS-specific induced pluripotent stem cells</article-title>
<source/>Cardiovasc Res
          <year>2012</year>
<volume>95</volume>
<fpage>419</fpage>
<lpage>429</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvs206</pub-id>
<pub-id pub-id-type="pmid">22739119</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Loh</surname>
<given-names>LJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Stem Cell Res Ther
          <year>2015</year>
<volume>6</volume>
<fpage>39</fpage>
<pub-id pub-id-type="doi">10.1186/s13287-015-0027-z</pub-id>
<pub-id pub-id-type="pmid">25889101</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Terrenoire</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Osteen</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biophysical properties of slow potassium channels in human embryonic stem cell derived cardiomyocytes implicate subunit stoichiometry</article-title>
<source/>J Physiol
          <year>2011</year>
<volume>589</volume>
<fpage>6093</fpage>
<lpage>6104</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.2011.220863</pub-id>
<pub-id pub-id-type="pmid">22025662</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volders</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Stengl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Opstal</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Gerlach</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Spatjens</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Beekman</surname>
<given-names>JD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Probing the contribution of IKs to canine ventricular repolarization: key role for beta-adrenergic receptor stimulation</article-title>
<source/>Circulation
          <year>2003</year>
<volume>107</volume>
<fpage>2753</fpage>
<lpage>2760</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.0000068344.54010.B3</pub-id>
<pub-id pub-id-type="pmid">12756150</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jost</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Virag</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bitay</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takacs</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lengyel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Biliczki</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle</article-title>
<source/>Circulation
          <year>2005</year>
<volume>112</volume>
<fpage>1392</fpage>
<lpage>1399</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.550111</pub-id>
<pub-id pub-id-type="pmid">16129791</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Towart</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Linders</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Hermans</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Rohrbacher</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van der Linde</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Ercken</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?</article-title>
<source/>J Pharmacol Toxicol Methods
          <year>2009</year>
<volume>60</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/j.vascn.2009.04.197</pub-id>
<pub-id pub-id-type="pmid">19439185</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhamoon</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Jalife</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The inward rectifier current (IK1) controls cardiac excitability and is involved in arrhythmogenesis</article-title>
<source/>Heart Rhythm
          <year>2005</year>
<volume>2</volume>
<fpage>316</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="doi">10.1016/j.hrthm.2004.11.012</pub-id>
<pub-id pub-id-type="pmid">15851327</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<mixed-citation publication-type="other">Meijer van Putten RM, Mengarelli I, Guan K, Zegers JG, van Ginneken AC, Verkerk AO<italic>, et al.</italic> Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1. Front Physiol 2015;6:7.</mixed-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verkerk</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Wilders</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van Borren</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Broekhuis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pacemaker current (I(f)) in the human sinoatrial node</article-title>
<source/>Eur Heart J
          <year>2007</year>
<volume>28</volume>
<fpage>2472</fpage>
<lpage>2478</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehm339</pub-id>
<pub-id pub-id-type="pmid">17823213</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Chemaly</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Magaud</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Patri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jayle</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Guinamard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bois</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The heart rate-lowering agent ivabradine inhibits the pacemaker current I(f) in human atrial myocytes</article-title>
<source/>J Cardiovasc Electrophysiol
          <year>2007</year>
<volume>18</volume>
<fpage>1190</fpage>
<lpage>1196</lpage>
<pub-id pub-id-type="doi">10.1111/j.1540-8167.2007.00955.x</pub-id>
<pub-id pub-id-type="pmid">17850290</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoppe</surname>
<given-names>UC</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sudkamp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beuckelmann</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human hearts</article-title>
<source/>Circulation
          <year>1998</year>
<volume>97</volume>
<fpage>55</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.97.1.55</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stillitano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lonardo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zicha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Varro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cerbai</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mugelli</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular basis of funny current (If) in normal and failing human heart</article-title>
<source/>J Mol Cell Cardiol
          <year>2008</year>
<volume>45</volume>
<fpage>289</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2008.04.013</pub-id>
<pub-id pub-id-type="pmid">18556018</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bers</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Despa</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts</article-title>
<source/>J Pharmacol Sci
          <year>2006</year>
<volume>100</volume>
<fpage>315</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1254/jphs.CPJ06001X</pub-id>
<pub-id pub-id-type="pmid">16552170</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neef</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>LS</given-names>
</name>
</person-group>
<article-title>Novel aspects of excitation-contraction coupling in heart failure</article-title>
<source/>Basic Res Cardiol
          <year>2013</year>
<volume>108</volume>
<fpage>360</fpage>
<pub-id pub-id-type="doi">10.1007/s00395-013-0360-2</pub-id>
<pub-id pub-id-type="pmid">23740218</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Despa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bers</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Na(+) transport in the normal and failing heart—remember the balance</article-title>
<source/>J Mol Cell Cardiol
          <year>2013</year>
<volume>61</volume>
<fpage>2</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.04.011</pub-id>
<pub-id pub-id-type="pmid">23608603</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baartscheer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Borren</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Sodium ion transporters as new therapeutic targets in heart failure</article-title>
<source/>Cardiovasc Hematol Agents Med Chem
          <year>2008</year>
<volume>6</volume>
<fpage>229</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.2174/187152508785909546</pub-id>
<pub-id pub-id-type="pmid">18855635</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itzhaki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mizrahi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Zwi-Dantsis</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Arbel</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Calcium handling in human induced pluripotent stem cell derived cardiomyocytes</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0018037</pub-id>
<pub-id pub-id-type="pmid">21483779</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spencer</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Sears</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>CC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia</article-title>
<source/>Stem Cell Reports
          <year>2014</year>
<volume>3</volume>
<fpage>269</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2014.06.003</pub-id>
<pub-id pub-id-type="pmid">25254341</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devalla</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Gelinas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Aburawi</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Beqqali</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Goyette</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Freund</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT</article-title>
<source/>EMBO molecular medicine
          <year>2016</year>
<volume>8</volume>
<fpage>1390</fpage>
<lpage>1408</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201505719</pub-id>
<pub-id pub-id-type="pmid">27861123</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kornreich</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>The patch clamp technique: principles and technical considerations</article-title>
<source/>J Vet Cardiol
          <year>2007</year>
<volume>9</volume>
<fpage>25</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.jvc.2007.02.001</pub-id>
<pub-id pub-id-type="pmid">17689466</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yajuan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhiyuan</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>A comparison of the performance and application differences between manual and automated patch-clamp techniques</article-title>
<source/>Curr Chem Genomics
          <year>2012</year>
<volume>6</volume>
<fpage>87</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.2174/1875397301206010087</pub-id>
<pub-id pub-id-type="pmid">23346269</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farre</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fertig</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>HTS techniques for patch clamp-based ion channel screening—advances and economy</article-title>
<source/>Expert Opin Drug Discov
          <year>2012</year>
<volume>7</volume>
<fpage>515</fpage>
<lpage>524</lpage>
<pub-id pub-id-type="doi">10.1517/17460441.2012.682056</pub-id>
<pub-id pub-id-type="pmid">22507077</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruggemann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Farre</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Haarmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Haythornthwaite</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kreir</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stoelzle</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Planar patch clamp: advances in electrophysiology</article-title>
<source/>Methods Mol Biol
          <year>2008</year>
<volume>491</volume>
<fpage>165</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-59745-526-8_13</pub-id>
<pub-id pub-id-type="pmid">18998092</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verheijck</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Wilders</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bouman</surname>
<given-names>LN</given-names>
</name>
</person-group>
<article-title>Atrio-sinus interaction demonstrated by blockade of the rapid delayed rectifier current</article-title>
<source/>Circulation
          <year>2002</year>
<volume>105</volume>
<fpage>880</fpage>
<lpage>885</lpage>
<pub-id pub-id-type="doi">10.1161/hc0702.104128</pub-id>
<pub-id pub-id-type="pmid">11854131</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>AD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mechanism of automaticity in cardiomyocytes derived from human induced pluripotent stem cells</article-title>
<source/>J Mol Cell Cardiol
          <year>2015</year>
<volume>81</volume>
<fpage>81</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.01.013</pub-id>
<pub-id pub-id-type="pmid">25644533</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Reppel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nguemo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mohammad</surname>
<given-names>FI</given-names>
</name>
<name>
<surname>Kuzmenkin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hescheler</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human pluripotent stem cell-derived cardiomyocytes: response to TTX and lidocaine reveals strong cell to cell variability</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0045963</pub-id>
<pub-id pub-id-type="pmid">23029342</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Hsing</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>HT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Trypsin-induced proteome alteration during cell subculture in mammalian cells</article-title>
<source/>J Biomed Sci
          <year>2010</year>
<volume>17</volume>
<fpage>36</fpage>
<pub-id pub-id-type="doi">10.1186/1423-0127-17-36</pub-id>
<pub-id pub-id-type="pmid">20459778</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajamohan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kalra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Duc Hoang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>George</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Staniforth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Automated electrophysiological and pharmacological evaluation of human pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Stem Cells Dev
          <year>2016</year>
<volume>25</volume>
<fpage>439</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="doi">10.1089/scd.2015.0253</pub-id>
<pub-id pub-id-type="pmid">26906236</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braam</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Tertoolen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>van de Stolpe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Passier</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mummery</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes</article-title>
<source/>Stem Cell Res
          <year>2010</year>
<volume>4</volume>
<fpage>107</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1016/j.scr.2009.11.004</pub-id>
<pub-id pub-id-type="pmid">20034863</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<mixed-citation publication-type="other">Tertoolen LG, Braam SR, van Meer BJ, Passier R, Mummery CL. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun. 2017. doi:10.1016/j.bbrc.2017.01.151.</mixed-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Klos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bollensdorff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ewart</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kamp</surname>
<given-names>TJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers</article-title>
<source/>Circ Res
          <year>2012</year>
<volume>110</volume>
<fpage>1556</fpage>
<lpage>1563</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.262535</pub-id>
<pub-id pub-id-type="pmid">22570367</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Siu</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>HF</given-names>
</name>
</person-group>
<article-title>Overexpression of myocardin induces partial transdifferentiation of human-induced pluripotent stem cell-derived mesenchymal stem cells into cardiomyocytes</article-title>
<source/>Physiol Rep
          <year>2014</year>
<volume>2</volume>
<pub-id pub-id-type="pmid">24744906</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turnbull</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Karakikes</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Serrao</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Backeris</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium</article-title>
<source/>FASEB J
          <year>2014</year>
<volume>28</volume>
<fpage>644</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="doi">10.1096/fj.13-228007</pub-id>
<pub-id pub-id-type="pmid">24174427</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shinnawi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Maizels</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shaheen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gepstein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arbel</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Monitoring human-induced pluripotent stem cell-derived cardiomyocytes with genetically encoded calcium and voltage fluorescent reporters</article-title>
<source/>Stem Cell Reports
          <year>2015</year>
<volume>5</volume>
<fpage>582</fpage>
<lpage>596</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2015.08.009</pub-id>
<pub-id pub-id-type="pmid">26372632</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bedut</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seminatore-Nole</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lamamy</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Caignard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boutin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Nosjean</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes</article-title>
<source/>Am J Physiol Heart Circ Physiol
          <year>2016</year>
<volume>311</volume>
<fpage>H44</fpage>
<lpage>H53</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00793.2015</pub-id>
<pub-id pub-id-type="pmid">27199128</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giles</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Noble</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Rigorous phenotyping of cardiac iPSC preparations requires knowledge of their resting potential(s)</article-title>
<source/>Biophys J
          <year>2016</year>
<volume>110</volume>
<fpage>278</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1016/j.bpj.2015.06.070</pub-id>
<pub-id pub-id-type="pmid">26745430</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kane</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Hellen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Terracciano</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>The fallacy of assigning chamber specificity to iPSC cardiac myocytes from action potential morphology</article-title>
<source/>Biophys J
          <year>2016</year>
<volume>110</volume>
<fpage>281</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1016/j.bpj.2015.08.052</pub-id>
<pub-id pub-id-type="pmid">26745431</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bett</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Rasmusson</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Action potential shape is a crucial measure of cell type of stem cell-derived cardiomyocytes</article-title>
<source/>Biophys J
          <year>2016</year>
<volume>110</volume>
<fpage>284</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1016/j.bpj.2015.11.026</pub-id>
<pub-id pub-id-type="pmid">26745432</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Majdi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Talantova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Spiering</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Non-cardiomyocytes influence the electrophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation</article-title>
<source/>Stem Cells Dev
          <year>2010</year>
<volume>19</volume>
<fpage>783</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="doi">10.1089/scd.2009.0349</pub-id>
<pub-id pub-id-type="pmid">20001453</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tohyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hishiki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nagahata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Matsuura</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Cell Stem Cell
          <year>2013</year>
<volume>12</volume>
<fpage>127</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2012.09.013</pub-id>
<pub-id pub-id-type="pmid">23168164</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kita-Matsuo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Barcova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prigozhina</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Salomonis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jacot</surname>
<given-names>JG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes</article-title>
<source/>PLoS One
          <year>2009</year>
<volume>4</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0005046</pub-id>
<pub-id pub-id-type="pmid">19352491</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieu</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Chiamvimonvat</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>McNerney</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Huser</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes</article-title>
<source/>Circ Arrhythm Electrophysiol
          <year>2013</year>
<volume>6</volume>
<fpage>191</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCEP.111.973420</pub-id>
<pub-id pub-id-type="pmid">23392582</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaidyanathan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Markandeya</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kamp</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Makielski</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>January</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Eckhardt</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>IK1-enhanced human-induced pluripotent stem cell-derived cardiomyocytes: an improved cardiomyocyte model to investigate inherited arrhythmia syndromes</article-title>
<source/>Am J Physiol Heart Circ Physiol
          <year>2016</year>
<volume>310</volume>
<fpage>H1611</fpage>
<lpage>H1621</lpage>
<pub-id pub-id-type="doi">10.1152/ajpheart.00481.2015</pub-id>
<pub-id pub-id-type="pmid">27059077</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bett</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Lis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cimato</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Tzanakakis</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Electronic "expression" of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells</article-title>
<source/>Heart Rhythm
          <year>2013</year>
<volume>10</volume>
<fpage>1903</fpage>
<lpage>1910</lpage>
<pub-id pub-id-type="doi">10.1016/j.hrthm.2013.09.061</pub-id>
<pub-id pub-id-type="pmid">24055949</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilders</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Dynamic clamp: a powerful tool in cardiac electrophysiology</article-title>
<source/>J Physiol
          <year>2006</year>
<volume>576</volume>
<fpage>349</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.2006.115840</pub-id>
<pub-id pub-id-type="pmid">16873403</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Spazzolini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Crotti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bathen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Amlie</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Timothy</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome</article-title>
<source/>Circulation
          <year>2006</year>
<volume>113</volume>
<fpage>783</fpage>
<lpage>790</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.592899</pub-id>
<pub-id pub-id-type="pmid">16461811</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fodstad</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bendahhou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rougier</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Laitinen-Forsblom</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Barhanin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abriel</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular characterization of two founder mutations causing long QT syndrome and identification of compound heterozygous patients</article-title>
<source/>Ann Med
          <year>2006</year>
<volume>38</volume>
<fpage>294</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1080/07853890600756065</pub-id>
<pub-id pub-id-type="pmid">16754261</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stallmeyer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fleischmann</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Schulze-Bahr</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction</article-title>
<source/>Basic Res Cardiol
          <year>2016</year>
<volume>111</volume>
<fpage>14</fpage>
<pub-id pub-id-type="doi">10.1007/s00395-016-0530-0</pub-id>
<pub-id pub-id-type="pmid">26803770</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Awari</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>Uche-Anya</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Yabe</surname>
<given-names>YA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dual optical recordings for action potentials and calcium handling in induced pluripotent stem cell models of cardiac arrhythmias using genetically encoded fluorescent indicators</article-title>
<source/>Stem Cells Transl Med
          <year>2015</year>
<volume>4</volume>
<fpage>468</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.5966/sctm.2014-0245</pub-id>
<pub-id pub-id-type="pmid">25769651</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Remme</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects</article-title>
<source/>J Physiol
          <year>2013</year>
<volume>591</volume>
<fpage>4099</fpage>
<lpage>4116</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.2013.256461</pub-id>
<pub-id pub-id-type="pmid">23818691</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Remme</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Bezzina</surname>
<given-names>CR</given-names>
</name>
</person-group>
<article-title>Sodium channel (dys)function and cardiac arrhythmias</article-title>
<source/>Cardiovasc Ther
          <year>2010</year>
<volume>28</volume>
<fpage>287</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1111/j.1755-5922.2010.00210.x</pub-id>
<pub-id pub-id-type="pmid">20645984</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieve</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>van der Werf</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>Catecholaminergic polymorphic ventricular tachycardia</article-title>
<source/>Circ J
          <year>2016</year>
<volume>80</volume>
<fpage>1285</fpage>
<lpage>1291</lpage>
<pub-id pub-id-type="doi">10.1253/circj.CJ-16-0326</pub-id>
<pub-id pub-id-type="pmid">27180891</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itzhaki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Maizels</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gepstein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arbel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Caspi</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells</article-title>
<source/>J Am Coll Cardiol
          <year>2012</year>
<volume>60</volume>
<fpage>990</fpage>
<lpage>1000</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2012.02.066</pub-id>
<pub-id pub-id-type="pmid">22749309</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preininger</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Jha</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses</article-title>
<source/>Dis Model Mech
          <year>2016</year>
<volume>9</volume>
<fpage>927</fpage>
<lpage>939</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.026823</pub-id>
<pub-id pub-id-type="pmid">27491078</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<mixed-citation publication-type="other">Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO molecular medicine. 2012;4:180–91.</mixed-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penttinen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Swan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vanninen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Paavola</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lahtinen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Kontula</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antiarrhythmic effects of dantrolene in patients with catecholaminergic polymorphic ventricular tachycardia and replication of the responses using iPSC models</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0125366</pub-id>
<pub-id pub-id-type="pmid">25955245</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Pasquale</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lodola</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Miragoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Denegri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Avelino-Cruz</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Buonocore</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia</article-title>
<source/>Cell Death Dis
          <year>2013</year>
<volume>4</volume>
<pub-id pub-id-type="doi">10.1038/cddis.2013.369</pub-id>
<pub-id pub-id-type="pmid">24113177</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Makiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wuriyanghai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kamakura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishiuchi</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Patient-specific human induced pluripotent stem cell model assessed with electrical pacing validates S107 as a potential therapeutic agent for catecholaminergic polymorphic ventricular tachycardia</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<pub-id pub-id-type="doi">10.1371/journal.pone.0164795</pub-id>
<pub-id pub-id-type="pmid">27764147</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lodola</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Morone</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Denegri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bongianino</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nakahama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rutigliano</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia</article-title>
<source/>Cell Death Dis
          <year>2016</year>
<volume>7</volume>
<pub-id pub-id-type="doi">10.1038/cddis.2016.304</pub-id>
<pub-id pub-id-type="pmid">27711080</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haron-Khun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weisbrod</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yadin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Behar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peretz</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SK4 K+ channels are therapeutic targets for the treatment of cardiac arrhythmias</article-title>
<source/>EMBO molecular medicine
          <year>2017</year>
<volume>9</volume>
<fpage>415</fpage>
<lpage>429</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201606937</pub-id>
<pub-id pub-id-type="pmid">28219898</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Medway</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Georgiou</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes</article-title>
<source/>Eur Heart J
          <year>2014</year>
<volume>35</volume>
<fpage>1078</fpage>
<lpage>1087</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/eht067</pub-id>
<pub-id pub-id-type="pmid">23470493</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<mixed-citation publication-type="other">Stillitano F, Hansen J, Kong CW, Karakikes I, Funck-Brentano C, Geng L, et al. Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. eLife. 2017;6:e19406.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>